EP1660454A1 - Composes azacycliques convenant comme inhibiteurs des canaux specifiques des neurones sensoriels - Google Patents
Composes azacycliques convenant comme inhibiteurs des canaux specifiques des neurones sensorielsInfo
- Publication number
- EP1660454A1 EP1660454A1 EP04743288A EP04743288A EP1660454A1 EP 1660454 A1 EP1660454 A1 EP 1660454A1 EP 04743288 A EP04743288 A EP 04743288A EP 04743288 A EP04743288 A EP 04743288A EP 1660454 A1 EP1660454 A1 EP 1660454A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- dihydro
- phenyl
- defined above
- isoquinolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000001953 sensory effect Effects 0.000 title claims description 22
- 239000003112 inhibitor Substances 0.000 title description 5
- 150000004030 azacyclic compounds Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 168
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims description 210
- 125000000217 alkyl group Chemical group 0.000 claims description 189
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 128
- 125000001424 substituent group Chemical group 0.000 claims description 104
- -1 hydroxy, amino Chemical group 0.000 claims description 76
- 125000000623 heterocyclic group Chemical group 0.000 claims description 69
- 125000003545 alkoxy group Chemical group 0.000 claims description 59
- 150000002367 halogens Chemical class 0.000 claims description 49
- 229910052736 halogen Inorganic materials 0.000 claims description 48
- 125000001188 haloalkyl group Chemical group 0.000 claims description 43
- 125000001072 heteroaryl group Chemical group 0.000 claims description 42
- 239000001257 hydrogen Substances 0.000 claims description 39
- 229910052739 hydrogen Inorganic materials 0.000 claims description 39
- 208000002193 Pain Diseases 0.000 claims description 38
- 125000004995 haloalkylthio group Chemical group 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 35
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 35
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 33
- 125000005843 halogen group Chemical group 0.000 claims description 32
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 30
- 125000004414 alkyl thio group Chemical group 0.000 claims description 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
- 125000004122 cyclic group Chemical group 0.000 claims description 26
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 25
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 23
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 15
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 14
- 125000004076 pyridyl group Chemical group 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 11
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 11
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 9
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 9
- 208000000094 Chronic Pain Diseases 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000002950 monocyclic group Chemical group 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000001544 thienyl group Chemical group 0.000 claims description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 125000000335 thiazolyl group Chemical group 0.000 claims description 8
- 125000001425 triazolyl group Chemical group 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000004193 piperazinyl group Chemical group 0.000 claims description 7
- 208000005298 acute pain Diseases 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
- 208000016192 Demyelinating disease Diseases 0.000 claims description 5
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 230000004907 flux Effects 0.000 claims description 4
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 229910001415 sodium ion Inorganic materials 0.000 claims description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 3
- 206010069632 Bladder dysfunction Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 3
- 125000006766 (C2-C6) alkynyloxy group Chemical group 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 239000006199 nebulizer Substances 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 abstract description 2
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000004090 neuroprotective agent Substances 0.000 abstract 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 233
- 230000014759 maintenance of location Effects 0.000 description 226
- 238000001819 mass spectrum Methods 0.000 description 226
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 61
- 238000006243 chemical reaction Methods 0.000 description 55
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 52
- 239000002904 solvent Substances 0.000 description 52
- 239000000243 solution Substances 0.000 description 47
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 46
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 39
- 239000011541 reaction mixture Substances 0.000 description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 32
- 230000036407 pain Effects 0.000 description 27
- 238000003818 flash chromatography Methods 0.000 description 25
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 24
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 24
- 239000007787 solid Substances 0.000 description 22
- 239000003921 oil Substances 0.000 description 21
- 235000019198 oils Nutrition 0.000 description 21
- 238000010561 standard procedure Methods 0.000 description 21
- 108091006146 Channels Proteins 0.000 description 17
- 239000012071 phase Substances 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- 150000001412 amines Chemical class 0.000 description 16
- 235000019439 ethyl acetate Nutrition 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000002585 base Substances 0.000 description 15
- 239000000460 chlorine Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- 108010052164 Sodium Channels Proteins 0.000 description 13
- 102000018674 Sodium Channels Human genes 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 11
- 206010010904 Convulsion Diseases 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000007832 Na2SO4 Substances 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 8
- 229910052801 chlorine Inorganic materials 0.000 description 8
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 8
- 150000002576 ketones Chemical class 0.000 description 8
- 239000012280 lithium aluminium hydride Substances 0.000 description 8
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 8
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 7
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 235000015424 sodium Nutrition 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 5
- 230000009610 hypersensitivity Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 208000004296 neuralgia Diseases 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 4
- BFMHBXSJYJYTLY-UHFFFAOYSA-N 2-benzyl-4-methoxy-1,3-dihydroisoindole Chemical compound C1C=2C(OC)=CC=CC=2CN1CC1=CC=CC=C1 BFMHBXSJYJYTLY-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 229940080818 propionamide Drugs 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- NJPUIIJXFYTYRK-UHFFFAOYSA-N 2-(2-nitrophenoxy)-1-phenylethanone Chemical compound [O-][N+](=O)C1=CC=CC=C1OCC(=O)C1=CC=CC=C1 NJPUIIJXFYTYRK-UHFFFAOYSA-N 0.000 description 3
- WRBMEYKOZIOREC-UHFFFAOYSA-N 2-(3,4-dihydro-1h-isoquinolin-2-yl)-n-(3,3-diphenylpropyl)acetamide Chemical compound C1CC2=CC=CC=C2CN1CC(=O)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 WRBMEYKOZIOREC-UHFFFAOYSA-N 0.000 description 3
- TWDSRTOLLXKSSP-UHFFFAOYSA-N 2-(8-amino-3,4-dihydro-1h-isoquinolin-2-yl)-n-(4,4-diphenylbutyl)acetamide Chemical compound C1C=2C(N)=CC=CC=2CCN1CC(=O)NCCCC(C=1C=CC=CC=1)C1=CC=CC=C1 TWDSRTOLLXKSSP-UHFFFAOYSA-N 0.000 description 3
- XJOLYGFCZOFURL-UHFFFAOYSA-N 2-chloro-1-(3,4-dihydro-1h-isoquinolin-2-yl)ethanone Chemical compound C1=CC=C2CN(C(=O)CCl)CCC2=C1 XJOLYGFCZOFURL-UHFFFAOYSA-N 0.000 description 3
- QBEYUVIGABSXEU-UHFFFAOYSA-N 7-methoxy-3,4-dihydro-2h-isoquinolin-1-one Chemical compound C1CNC(=O)C2=CC(OC)=CC=C21 QBEYUVIGABSXEU-UHFFFAOYSA-N 0.000 description 3
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 3
- 206010000117 Abnormal behaviour Diseases 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- 108090000862 Ion Channels Proteins 0.000 description 3
- 208000019022 Mood disease Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 206010034010 Parkinsonism Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 125000004321 azepin-2-yl group Chemical group [H]N1C([H])=C([H])C([H])=C([H])C([H])=C1* 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 235000013681 dietary sucrose Nutrition 0.000 description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 3
- 229940071648 metered dose inhaler Drugs 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- HUDRTKKPTMCDFI-UHFFFAOYSA-N n-(2-benzhydrylsulfanylethyl)-2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1C=2C(OC)=CC=CC=2CCN1CC(=O)NCCSC(C=1C=CC=CC=1)C1=CC=CC=C1 HUDRTKKPTMCDFI-UHFFFAOYSA-N 0.000 description 3
- YNIDNLNUYCFFTA-UHFFFAOYSA-N n-benzhydryl-2-chloroacetamide Chemical compound C=1C=CC=CC=1C(NC(=O)CCl)C1=CC=CC=C1 YNIDNLNUYCFFTA-UHFFFAOYSA-N 0.000 description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 description 3
- 150000002923 oximes Chemical class 0.000 description 3
- 210000001428 peripheral nervous system Anatomy 0.000 description 3
- KVGDDIMCYFJEOB-UHFFFAOYSA-N phenoxazine-10-carboxylic acid Chemical compound C1=CC=C2N(C(=O)O)C3=CC=CC=C3OC2=C1 KVGDDIMCYFJEOB-UHFFFAOYSA-N 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 3
- 229950010357 tetrodotoxin Drugs 0.000 description 3
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 3
- RXMTUVIKZRXSSM-UHFFFAOYSA-N 2,2-diphenylethanamine Chemical compound C=1C=CC=CC=1C(CN)C1=CC=CC=C1 RXMTUVIKZRXSSM-UHFFFAOYSA-N 0.000 description 2
- HZFGFFHCLDVOBV-UHFFFAOYSA-N 2-(1,3-dihydroisoindol-2-yl)-1-phenoxazin-10-ylethanone Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)CN1CC2=CC=CC=C2C1 HZFGFFHCLDVOBV-UHFFFAOYSA-N 0.000 description 2
- WKTXZFQHIRHKSL-UHFFFAOYSA-N 2-(1,3-dihydroisoindol-2-yl)-n-(3,3-diphenylpropyl)acetamide Chemical compound C1C2=CC=CC=C2CN1CC(=O)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 WKTXZFQHIRHKSL-UHFFFAOYSA-N 0.000 description 2
- SENZOKBXMMMDGN-UHFFFAOYSA-N 2-(5-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-phenoxazin-10-ylethanone Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)CN1CC(C=CC=C2O)=C2CC1 SENZOKBXMMMDGN-UHFFFAOYSA-N 0.000 description 2
- FBLDJVLUABMOQE-UHFFFAOYSA-N 2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-phenothiazin-10-ylethanone Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1C(=O)CN1CCC(C=C(C(=C2)OC)OC)=C2C1 FBLDJVLUABMOQE-UHFFFAOYSA-N 0.000 description 2
- SNUASSHDRNMJSE-UHFFFAOYSA-N 2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-n',n'-diphenylacetohydrazide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CC(=O)NN(C=1C=CC=CC=1)C1=CC=CC=C1 SNUASSHDRNMJSE-UHFFFAOYSA-N 0.000 description 2
- ONZWNRPIDYURAB-UHFFFAOYSA-N 2-(8-acetamido-3,4-dihydro-1h-isoquinolin-2-yl)-n-(4,4-diphenylbutyl)acetamide Chemical compound C1C=2C(NC(=O)C)=CC=CC=2CCN1CC(=O)NCCCC(C=1C=CC=CC=1)C1=CC=CC=C1 ONZWNRPIDYURAB-UHFFFAOYSA-N 0.000 description 2
- HKPCNCNSRQRXDJ-UHFFFAOYSA-N 2-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-[2-(trifluoromethyl)phenothiazin-10-yl]ethanone Chemical compound C12=CC=CC=C2SC2=CC=C(C(F)(F)F)C=C2N1C(=O)CN1CCC(C=CC=C2O)=C2C1 HKPCNCNSRQRXDJ-UHFFFAOYSA-N 0.000 description 2
- GBZNFYCZZRTMNO-UHFFFAOYSA-N 2-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-phenothiazin-10-ylethanone Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1C(=O)CN1CCC(C=CC=C2O)=C2C1 GBZNFYCZZRTMNO-UHFFFAOYSA-N 0.000 description 2
- PYTVAAMYTJOPTN-UHFFFAOYSA-N 2-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)-n',n'-diphenylacetohydrazide Chemical compound C1C=2C(O)=CC=CC=2CCN1CC(=O)NN(C=1C=CC=CC=1)C1=CC=CC=C1 PYTVAAMYTJOPTN-UHFFFAOYSA-N 0.000 description 2
- WHMICNASXKNTOX-UHFFFAOYSA-N 2-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)-n,n-bis(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1N(C=1C=CC(OC)=CC=1)C(=O)CN1CC2=C(O)C=CC=C2CC1 WHMICNASXKNTOX-UHFFFAOYSA-N 0.000 description 2
- SLLBCNQLMSSAPM-UHFFFAOYSA-N 2-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)-n,n-diphenylacetamide Chemical compound C1C=2C(O)=CC=CC=2CCN1CC(=O)N(C=1C=CC=CC=1)C1=CC=CC=C1 SLLBCNQLMSSAPM-UHFFFAOYSA-N 0.000 description 2
- QQCBSCFOELMJPD-UHFFFAOYSA-N 2-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)-n-(2-phenoxyphenyl)acetamide Chemical compound C1C=2C(O)=CC=CC=2CCN1CC(=O)NC1=CC=CC=C1OC1=CC=CC=C1 QQCBSCFOELMJPD-UHFFFAOYSA-N 0.000 description 2
- LCOZFZZEKLKLMQ-UHFFFAOYSA-N 2-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)-n-(9h-xanthen-9-yl)acetamide Chemical compound C12=CC=CC=C2OC2=CC=CC=C2C1NC(=O)CN1CCC(C=CC=C2O)=C2C1 LCOZFZZEKLKLMQ-UHFFFAOYSA-N 0.000 description 2
- UDDZJQLVMZFZAX-UHFFFAOYSA-N 2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-(2-methylsulfanylphenothiazin-10-yl)ethanone Chemical compound C12=CC=CC=C2SC2=CC=C(SC)C=C2N1C(=O)CN1CCC(C=CC=C2OC)=C2C1 UDDZJQLVMZFZAX-UHFFFAOYSA-N 0.000 description 2
- CNHJXMMFORRZHA-UHFFFAOYSA-N 2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-[2-(trifluoromethyl)phenothiazin-10-yl]ethanone Chemical compound C12=CC=CC=C2SC2=CC=C(C(F)(F)F)C=C2N1C(=O)CN1CCC(C=CC=C2OC)=C2C1 CNHJXMMFORRZHA-UHFFFAOYSA-N 0.000 description 2
- VHOZJELTXRMMFK-UHFFFAOYSA-N 2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-phenoxazin-10-ylethanone Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)CN1CCC(C=CC=C2OC)=C2C1 VHOZJELTXRMMFK-UHFFFAOYSA-N 0.000 description 2
- LCHCANADDFRJPO-UHFFFAOYSA-N 2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-n,n-di(propan-2-yl)acetamide Chemical compound C1CN(CC(=O)N(C(C)C)C(C)C)CC2=C1C=CC=C2OC LCHCANADDFRJPO-UHFFFAOYSA-N 0.000 description 2
- ZZJIVCYXHYIFFX-UHFFFAOYSA-N 2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-n-(4-phenoxyphenyl)acetamide Chemical compound C1C=2C(OC)=CC=CC=2CCN1CC(=O)NC(C=C1)=CC=C1OC1=CC=CC=C1 ZZJIVCYXHYIFFX-UHFFFAOYSA-N 0.000 description 2
- CCSQQXLDZKHZHI-UHFFFAOYSA-N 2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-n-(9h-xanthen-9-yl)acetamide Chemical compound C12=CC=CC=C2OC2=CC=CC=C2C1NC(=O)CN1CCC(C=CC=C2OC)=C2C1 CCSQQXLDZKHZHI-UHFFFAOYSA-N 0.000 description 2
- JHKCXLDFMOJDND-UHFFFAOYSA-N 2-(benzhydrylamino)-1-(1,3-dihydroisoindol-2-yl)ethanone Chemical compound C1C2=CC=CC=C2CN1C(=O)CNC(C=1C=CC=CC=1)C1=CC=CC=C1 JHKCXLDFMOJDND-UHFFFAOYSA-N 0.000 description 2
- MXPZJSVEERAKPK-UHFFFAOYSA-N 2-(benzhydrylamino)-1-(3,4-dihydro-1h-isoquinolin-2-yl)ethanone Chemical compound C1CC2=CC=CC=C2CN1C(=O)CNC(C=1C=CC=CC=1)C1=CC=CC=C1 MXPZJSVEERAKPK-UHFFFAOYSA-N 0.000 description 2
- MQEVDBLUMCJYJD-UHFFFAOYSA-N 2-(dibenzylamino)-1-(3,4-dihydro-1h-isoquinolin-2-yl)ethanone Chemical compound C1CC2=CC=CC=C2CN1C(=O)CN(CC=1C=CC=CC=1)CC1=CC=CC=C1 MQEVDBLUMCJYJD-UHFFFAOYSA-N 0.000 description 2
- SMMJVXYVRUZQHM-UHFFFAOYSA-N 2-(dipyridin-2-ylmethylideneamino)oxy-1-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethanone Chemical compound C1C=2C(OC)=CC=CC=2CCN1C(=O)CON=C(C=1N=CC=CC=1)C1=CC=CC=N1 SMMJVXYVRUZQHM-UHFFFAOYSA-N 0.000 description 2
- PKZJLOCLABXVMC-UHFFFAOYSA-N 2-Methoxybenzaldehyde Chemical compound COC1=CC=CC=C1C=O PKZJLOCLABXVMC-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- DSZCDKTVMBGLGD-UHFFFAOYSA-N 2-chloro-n-(3,3-diphenylpropyl)acetamide Chemical compound C=1C=CC=CC=1C(CCNC(=O)CCl)C1=CC=CC=C1 DSZCDKTVMBGLGD-UHFFFAOYSA-N 0.000 description 2
- UKZYUBAWDVKZFR-UHFFFAOYSA-N 3-(5-amino-3,4-dihydro-1h-isoquinolin-2-yl)-n-(3,3-diphenylpropyl)propanamide Chemical compound C1CC=2C(N)=CC=CC=2CN1CCC(=O)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 UKZYUBAWDVKZFR-UHFFFAOYSA-N 0.000 description 2
- AOGGKPAQFJLCFW-UHFFFAOYSA-N 3-(8-amino-3,4-dihydro-1h-isoquinolin-2-yl)-n-(3,3-diphenylpropyl)propanamide Chemical compound C1C=2C(N)=CC=CC=2CCN1CCC(=O)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 AOGGKPAQFJLCFW-UHFFFAOYSA-N 0.000 description 2
- DCDSDKAYJZLMEX-UHFFFAOYSA-N 4-methoxy-2,3-dihydro-1h-isoindole Chemical compound COC1=CC=CC2=C1CNC2 DCDSDKAYJZLMEX-UHFFFAOYSA-N 0.000 description 2
- LTPVSOCPYWDIFU-UHFFFAOYSA-N 4-methoxyphenylethylamine Chemical compound COC1=CC=C(CCN)C=C1 LTPVSOCPYWDIFU-UHFFFAOYSA-N 0.000 description 2
- KWSLGOVYXMQPPX-UHFFFAOYSA-N 5-[3-(trifluoromethyl)phenyl]-2h-tetrazole Chemical compound FC(F)(F)C1=CC=CC(C2=NNN=N2)=C1 KWSLGOVYXMQPPX-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- HHZGHKIHHIKUHK-UHFFFAOYSA-N 8-methoxyisoquinoline Chemical compound C1=NC=C2C(OC)=CC=CC2=C1 HHZGHKIHHIKUHK-UHFFFAOYSA-N 0.000 description 2
- 208000000187 Abnormal Reflex Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 208000001408 Carbon monoxide poisoning Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000001387 Causalgia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 208000018380 Chemical injury Diseases 0.000 description 2
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 2
- 206010063057 Cystitis noninfective Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 208000030814 Eating disease Diseases 0.000 description 2
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 208000001738 Nervous System Trauma Diseases 0.000 description 2
- 208000001294 Nociceptive Pain Diseases 0.000 description 2
- 206010067013 Normal tension glaucoma Diseases 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 229910020667 PBr3 Inorganic materials 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- 208000037158 Partial Epilepsies Diseases 0.000 description 2
- 206010061334 Partial seizures Diseases 0.000 description 2
- 208000004983 Phantom Limb Diseases 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- WDOSFTZMBFYTED-UHFFFAOYSA-N [isothiocyanato(phenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(N=C=S)C1=CC=CC=C1 WDOSFTZMBFYTED-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N aminothiocarboxamide Natural products NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 235000014632 disordered eating Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 125000005059 halophenyl group Chemical group 0.000 description 2
- RKDJBXYFUGOJRU-UHFFFAOYSA-N hydron;7-methoxy-1,2,3,4-tetrahydroisoquinoline;chloride Chemical compound Cl.C1CNCC2=CC(OC)=CC=C21 RKDJBXYFUGOJRU-UHFFFAOYSA-N 0.000 description 2
- 206010020745 hyperreflexia Diseases 0.000 description 2
- 230000035859 hyperreflexia Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- ZIXWTPREILQLAC-UHFFFAOYSA-N isoquinolin-8-ol Chemical compound C1=NC=C2C(O)=CC=CC2=C1 ZIXWTPREILQLAC-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000002978 low tension glaucoma Diseases 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 2
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- YDOJEOGCVATVJI-UHFFFAOYSA-N methyl n-[2-(4-methoxyphenyl)ethyl]carbamate Chemical compound COC(=O)NCCC1=CC=C(OC)C=C1 YDOJEOGCVATVJI-UHFFFAOYSA-N 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- CNXVXLUOCNXZIH-UHFFFAOYSA-N n,n-dibenzyl-2-(8-ethoxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1C=2C(OCC)=CC=CC=2CCN1CC(=O)N(CC=1C=CC=CC=1)CC1=CC=CC=C1 CNXVXLUOCNXZIH-UHFFFAOYSA-N 0.000 description 2
- UKVLVDYKLIFPPW-UHFFFAOYSA-N n,n-dibenzyl-2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1C=2C(OC)=CC=CC=2CCN1CC(=O)N(CC=1C=CC=CC=1)CC1=CC=CC=C1 UKVLVDYKLIFPPW-UHFFFAOYSA-N 0.000 description 2
- FYAHIJVDJLLQHZ-UHFFFAOYSA-N n,n-dibenzyl-3-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)propanamide Chemical compound C1C=2C(OC)=CC=CC=2CCN1CCC(=O)N(CC=1C=CC=CC=1)CC1=CC=CC=C1 FYAHIJVDJLLQHZ-UHFFFAOYSA-N 0.000 description 2
- PMSUVDIJOPGMFU-UHFFFAOYSA-N n-(2-benzhydrylsulfinylethyl)-2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1C=2C(OC)=CC=CC=2CCN1CC(=O)NCCS(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 PMSUVDIJOPGMFU-UHFFFAOYSA-N 0.000 description 2
- LIWONMHMMQAESR-UHFFFAOYSA-N n-(3,3-diphenylpropyl)-2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1C=2C(OC)=CC=CC=2CCN1CC(=O)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 LIWONMHMMQAESR-UHFFFAOYSA-N 0.000 description 2
- DYSKVYYETCYMBH-UHFFFAOYSA-N n-(3-aminopyridin-2-yl)-n-(2-hydroxyphenyl)-2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1C=2C(OC)=CC=CC=2CCN1CC(=O)N(C=1C(=CC=CN=1)N)C1=CC=CC=C1O DYSKVYYETCYMBH-UHFFFAOYSA-N 0.000 description 2
- BFBYAHXBJFWJNL-UHFFFAOYSA-N n-(3-carbazol-9-ylpropyl)-2-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1CCCNC(=O)CN1CCC(C=CC=C2O)=C2C1 BFBYAHXBJFWJNL-UHFFFAOYSA-N 0.000 description 2
- KNIBJGQXQQNJBO-UHFFFAOYSA-N n-(4,4-diphenylbutyl)-2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1C=2C(OC)=CC=CC=2CCN1CC(=O)NCCCC(C=1C=CC=CC=1)C1=CC=CC=C1 KNIBJGQXQQNJBO-UHFFFAOYSA-N 0.000 description 2
- LOGWNTZWFCDJCN-UHFFFAOYSA-N n-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenothiazine-10-carboxamide Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1C(=O)NCCN1CCC(C=C(C(=C2)OC)OC)=C2C1 LOGWNTZWFCDJCN-UHFFFAOYSA-N 0.000 description 2
- HKLXOVCUFQZCQQ-UHFFFAOYSA-N n-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenoxazine-10-carboxamide Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)NCCN1CCC(C=C(C(=C2)OC)OC)=C2C1 HKLXOVCUFQZCQQ-UHFFFAOYSA-N 0.000 description 2
- PTXMNQGTYXBFJM-UHFFFAOYSA-N n-[2-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenothiazine-10-carboxamide Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1C(=O)NCCN1CCC(C=CC=C2O)=C2C1 PTXMNQGTYXBFJM-UHFFFAOYSA-N 0.000 description 2
- CSDRPLKVIMWNNM-UHFFFAOYSA-N n-[2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenothiazine-10-carboxamide Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1C(=O)NCCN1CCC(C=CC=C2OC)=C2C1 CSDRPLKVIMWNNM-UHFFFAOYSA-N 0.000 description 2
- HWJWAMLVERHOSL-UHFFFAOYSA-N n-[2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenoxazine-10-carboxamide Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)NCCN1CCC(C=CC=C2OC)=C2C1 HWJWAMLVERHOSL-UHFFFAOYSA-N 0.000 description 2
- LDLSFDIQUKUVDN-UHFFFAOYSA-N n-[3,3-bis(4-methoxyphenyl)propyl]-2-(1,3-dihydroisoindol-2-yl)acetamide Chemical compound C1=CC(OC)=CC=C1C(C=1C=CC(OC)=CC=1)CCNC(=O)CN1CC2=CC=CC=C2C1 LDLSFDIQUKUVDN-UHFFFAOYSA-N 0.000 description 2
- SSOOOSYSBOINIR-UHFFFAOYSA-N n-[3-(3,4-diacetamidophenyl)-3-phenylpropyl]-2-(3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1=C(NC(C)=O)C(NC(=O)C)=CC=C1C(C=1C=CC=CC=1)CCNC(=O)CN1CC2=CC=CC=C2CC1 SSOOOSYSBOINIR-UHFFFAOYSA-N 0.000 description 2
- NTAUBWQDOBNPEC-UHFFFAOYSA-N n-[bis(4-fluorophenyl)methyl]-2-(1,3-dihydroisoindol-2-yl)acetamide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)NC(=O)CN1CC2=CC=CC=C2C1 NTAUBWQDOBNPEC-UHFFFAOYSA-N 0.000 description 2
- CBQPXZXYSZCHQN-UHFFFAOYSA-N n-[bis(4-fluorophenyl)methyl]-2-(3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)NC(=O)CN1CC2=CC=CC=C2CC1 CBQPXZXYSZCHQN-UHFFFAOYSA-N 0.000 description 2
- LYEWBCHIXBKPEU-UHFFFAOYSA-N n-[bis(4-fluorophenyl)methyl]-2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CC(=O)NC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 LYEWBCHIXBKPEU-UHFFFAOYSA-N 0.000 description 2
- ZPSJLPNAMMVDQL-UHFFFAOYSA-N n-benzhydryl-2-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1C=2C(O)=CC=CC=2CCN1CC(=O)NC(C=1C=CC=CC=1)C1=CC=CC=C1 ZPSJLPNAMMVDQL-UHFFFAOYSA-N 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 208000002040 neurosyphilis Diseases 0.000 description 2
- 210000000929 nociceptor Anatomy 0.000 description 2
- 108091008700 nociceptors Proteins 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 208000027232 peripheral nervous system disease Diseases 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 229910001379 sodium hypophosphite Inorganic materials 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 231100000736 substance abuse Toxicity 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 208000002025 tabes dorsalis Diseases 0.000 description 2
- 125000005505 thiomorpholino group Chemical group 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- ZWVMLYRJXORSEP-LURJTMIESA-N (2s)-hexane-1,2,6-triol Chemical compound OCCCC[C@H](O)CO ZWVMLYRJXORSEP-LURJTMIESA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- JCKSOCLSFGDRMJ-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinolin-8-yl acetate Chemical class C1CNCC2=C1C=CC=C2OC(=O)C JCKSOCLSFGDRMJ-UHFFFAOYSA-N 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- NBXXHNNQYHDOTO-UHFFFAOYSA-N 1-(1,3-dihydroisoindol-2-yl)-2-phenoxazin-10-ylethanone Chemical compound C1C2=CC=CC=C2CN1C(=O)CN1C2=CC=CC=C2OC2=CC=CC=C21 NBXXHNNQYHDOTO-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- VZTHCUVDHGTSLC-UHFFFAOYSA-N 1-(2-acetylphenothiazin-10-yl)-2-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)ethanone Chemical compound C1CC2=CC=CC(O)=C2CN1CC(=O)N1C2=CC=CC=C2SC2=CC=C(C(=O)C)C=C21 VZTHCUVDHGTSLC-UHFFFAOYSA-N 0.000 description 1
- CZZDIIJOXFFUGL-UHFFFAOYSA-N 1-(2-acetylphenothiazin-10-yl)-2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethanone Chemical compound C12=CC=CC=C2SC2=CC=C(C(C)=O)C=C2N1C(=O)CN1CCC(C=CC=C2OC)=C2C1 CZZDIIJOXFFUGL-UHFFFAOYSA-N 0.000 description 1
- QZHZMZDQIKLRPW-UHFFFAOYSA-N 1-(2-chlorophenothiazin-10-yl)-2-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)ethanone Chemical compound C12=CC=CC=C2SC2=CC=C(Cl)C=C2N1C(=O)CN1CCC(C=CC=C2O)=C2C1 QZHZMZDQIKLRPW-UHFFFAOYSA-N 0.000 description 1
- GSHJLEPRMZVNAN-UHFFFAOYSA-N 1-(2-chlorophenothiazin-10-yl)-2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethanone Chemical compound C12=CC=CC=C2SC2=CC=C(Cl)C=C2N1C(=O)CN1CCC(C=CC=C2OC)=C2C1 GSHJLEPRMZVNAN-UHFFFAOYSA-N 0.000 description 1
- NWYOSYCFZYCYAH-UHFFFAOYSA-N 1-(3,4-dihydro-1h-isoquinolin-2-yl)-2-(2,2-diphenylethylamino)ethanone Chemical compound C1CC2=CC=CC=C2CN1C(=O)CNCC(C=1C=CC=CC=1)C1=CC=CC=C1 NWYOSYCFZYCYAH-UHFFFAOYSA-N 0.000 description 1
- MJEXHZWHSIKWKJ-UHFFFAOYSA-N 1-(3,4-dihydro-1h-isoquinolin-2-yl)-2-(3,3-diphenylpropylamino)ethanone Chemical compound C1CC2=CC=CC=C2CN1C(=O)CNCCC(C=1C=CC=CC=1)C1=CC=CC=C1 MJEXHZWHSIKWKJ-UHFFFAOYSA-N 0.000 description 1
- ATLQGZVLWOURFU-UHFFFAOYSA-N 1-(bromomethyl)-3,5-bis(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(CBr)=CC(C(F)(F)F)=C1 ATLQGZVLWOURFU-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- OZUNESHLKIIYAU-UHFFFAOYSA-N 1-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-(1,3-dihydroisoindol-2-yl)ethanone Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C(=O)CN2CC3=CC=CC=C3C2)CC1 OZUNESHLKIIYAU-UHFFFAOYSA-N 0.000 description 1
- PUQMNFGYUDUSBE-UHFFFAOYSA-N 1-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethanone Chemical compound C1C=2C(OC)=CC=CC=2CCN1CC(=O)N(CC1)CCN1C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 PUQMNFGYUDUSBE-UHFFFAOYSA-N 0.000 description 1
- NHIZNNTXHDOHHM-UHFFFAOYSA-N 1-benzhydryl-3-[2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]thiourea Chemical compound C1C=2C(OC)=CC=CC=2CCN1CCNC(=S)NC(C=1C=CC=CC=1)C1=CC=CC=C1 NHIZNNTXHDOHHM-UHFFFAOYSA-N 0.000 description 1
- BLMBNEVGYRXFNA-UHFFFAOYSA-N 1-methoxy-2,3-dimethylbenzene Chemical compound COC1=CC=CC(C)=C1C BLMBNEVGYRXFNA-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 1
- HLLGFGBLKOIZOM-UHFFFAOYSA-N 2,2-diphenylacetaldehyde Chemical compound C=1C=CC=CC=1C(C=O)C1=CC=CC=C1 HLLGFGBLKOIZOM-UHFFFAOYSA-N 0.000 description 1
- POUPMPIDJWMLKT-UHFFFAOYSA-N 2-(1,1-dimethoxy-3,4-dihydroisoquinolin-2-yl)-n-(4,4-diphenylbutyl)acetamide Chemical compound C1CC2=CC=CC=C2C(OC)(OC)N1CC(=O)NCCCC(C=1C=CC=CC=1)C1=CC=CC=C1 POUPMPIDJWMLKT-UHFFFAOYSA-N 0.000 description 1
- UVNOKVFQYNKXEA-UHFFFAOYSA-N 2-(1,3-dihydroisoindol-2-yl)-n-(2,2-diphenylethyl)acetamide Chemical compound C1C2=CC=CC=C2CN1CC(=O)NCC(C=1C=CC=CC=1)C1=CC=CC=C1 UVNOKVFQYNKXEA-UHFFFAOYSA-N 0.000 description 1
- SVKMMCTYOLVJEH-UHFFFAOYSA-N 2-(2,2-diphenylethyl)-3,4-dihydro-1h-isoquinoline Chemical compound C1CC2=CC=CC=C2CN1CC(C=1C=CC=CC=1)C1=CC=CC=C1 SVKMMCTYOLVJEH-UHFFFAOYSA-N 0.000 description 1
- WGOFHQHHDNJEQJ-UHFFFAOYSA-N 2-(2,2-diphenylethyl)-8-methoxy-3,4-dihydro-1h-isoquinoline Chemical compound C1C=2C(OC)=CC=CC=2CCN1CC(C=1C=CC=CC=1)C1=CC=CC=C1 WGOFHQHHDNJEQJ-UHFFFAOYSA-N 0.000 description 1
- KBIJVLMZAYENOJ-UHFFFAOYSA-N 2-(2,2-diphenylethylamino)-1-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethanone Chemical compound C1C=2C(OC)=CC=CC=2CCN1C(=O)CNCC(C=1C=CC=CC=1)C1=CC=CC=C1 KBIJVLMZAYENOJ-UHFFFAOYSA-N 0.000 description 1
- SCPHESNLTBGQKE-UHFFFAOYSA-N 2-(2-oxo-2-phenoxazin-10-ylethyl)-1,3-dihydroisoindole-4-carbonitrile Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)CN1CC2=C(C#N)C=CC=C2C1 SCPHESNLTBGQKE-UHFFFAOYSA-N 0.000 description 1
- VWOVZCAAPBVQPR-UHFFFAOYSA-N 2-(3,4-dihydro-1h-isoquinolin-2-yl)-n-(1,2-diphenylethyl)acetamide Chemical compound C1CC2=CC=CC=C2CN1CC(=O)NC(C=1C=CC=CC=1)CC1=CC=CC=C1 VWOVZCAAPBVQPR-UHFFFAOYSA-N 0.000 description 1
- HTSYPIHPOMZDFJ-UHFFFAOYSA-N 2-(3,4-dihydro-1h-isoquinolin-2-yl)-n-(1,3-diphenylpropan-2-yl)acetamide Chemical compound C1CC2=CC=CC=C2CN1CC(=O)NC(CC=1C=CC=CC=1)CC1=CC=CC=C1 HTSYPIHPOMZDFJ-UHFFFAOYSA-N 0.000 description 1
- OFOCZDFREVXPSD-UHFFFAOYSA-N 2-(3,4-dihydro-1h-isoquinolin-2-yl)-n-(1-phenylethyl)acetamide Chemical compound C1CC2=CC=CC=C2CN1CC(=O)NC(C)C1=CC=CC=C1 OFOCZDFREVXPSD-UHFFFAOYSA-N 0.000 description 1
- CENOAXGAWYVSHO-UHFFFAOYSA-N 2-(3,4-dihydro-1h-isoquinolin-2-yl)-n-(9h-fluoren-9-yl)acetamide Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1NC(=O)CN1CC2=CC=CC=C2CC1 CENOAXGAWYVSHO-UHFFFAOYSA-N 0.000 description 1
- DHJNRNWDVQVDQE-UHFFFAOYSA-N 2-(4-amino-1,3-dihydroisoindol-2-yl)-n,n-dibenzylacetamide Chemical compound C1C=2C(N)=CC=CC=2CN1CC(=O)N(CC=1C=CC=CC=1)CC1=CC=CC=C1 DHJNRNWDVQVDQE-UHFFFAOYSA-N 0.000 description 1
- UFRIEXHDZCKECC-UHFFFAOYSA-N 2-(4-amino-1,3-dihydroisoindol-2-yl)-n-(3,3-diphenylpropyl)acetamide Chemical compound C1C=2C(N)=CC=CC=2CN1CC(=O)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 UFRIEXHDZCKECC-UHFFFAOYSA-N 0.000 description 1
- WOFFPRZRVQNNGU-UHFFFAOYSA-N 2-(4-chloro-1,3-dihydroisoindol-2-yl)-1-phenoxazin-10-ylethanone Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)CN1CC(C=CC=C2Cl)=C2C1 WOFFPRZRVQNNGU-UHFFFAOYSA-N 0.000 description 1
- AFOMXBVLFGKQQG-UHFFFAOYSA-N 2-(4-hydroxy-1,3-dihydroisoindol-2-yl)-1-phenoxazin-10-ylethanone Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)CN1CC(C=CC=C2O)=C2C1 AFOMXBVLFGKQQG-UHFFFAOYSA-N 0.000 description 1
- BKDVRARDIBWHBT-UHFFFAOYSA-N 2-(4-methoxy-1,3-dihydroisoindol-2-yl)-1-phenoxazin-10-ylethanone Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)CN1CC(C=CC=C2OC)=C2C1 BKDVRARDIBWHBT-UHFFFAOYSA-N 0.000 description 1
- UDNPHVYQXQNXTL-UHFFFAOYSA-N 2-(4-methoxy-1,3-dihydroisoindol-2-yl)-1-phenoxazin-10-ylpropan-1-one Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)C(C)N1CC(C=CC=C2OC)=C2C1 UDNPHVYQXQNXTL-UHFFFAOYSA-N 0.000 description 1
- QNHRKHDFEHGFNQ-UHFFFAOYSA-N 2-(5-amino-3,4-dihydro-1h-isoquinolin-2-yl)-n-(2,2-diphenylethyl)acetamide Chemical compound C1CC=2C(N)=CC=CC=2CN1CC(=O)NCC(C=1C=CC=CC=1)C1=CC=CC=C1 QNHRKHDFEHGFNQ-UHFFFAOYSA-N 0.000 description 1
- IAKSAIKNAHKTMQ-UHFFFAOYSA-N 2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-(2-methylsulfanylphenothiazin-10-yl)ethanone Chemical compound C12=CC=CC=C2SC2=CC=C(SC)C=C2N1C(=O)CN1CCC(C=C(C(=C2)OC)OC)=C2C1 IAKSAIKNAHKTMQ-UHFFFAOYSA-N 0.000 description 1
- HIQXZVRHRFDSGX-UHFFFAOYSA-N 2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-[2-(trifluoromethyl)phenothiazin-10-yl]ethanone Chemical compound C12=CC=CC=C2SC2=CC=C(C(F)(F)F)C=C2N1C(=O)CN1CCC(C=C(C(=C2)OC)OC)=C2C1 HIQXZVRHRFDSGX-UHFFFAOYSA-N 0.000 description 1
- WHPATERACVEBJJ-UHFFFAOYSA-N 2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-n-(2,2-diphenylethyl)acetamide Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CC(=O)NCC(C=1C=CC=CC=1)C1=CC=CC=C1 WHPATERACVEBJJ-UHFFFAOYSA-N 0.000 description 1
- FTIVPPVBGXLMRG-UHFFFAOYSA-N 2-(6,8-dihydro-5h-1,7-naphthyridin-7-yl)-1-phenoxazin-10-ylethanone Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)CN1CC2=NC=CC=C2CC1 FTIVPPVBGXLMRG-UHFFFAOYSA-N 0.000 description 1
- ZLEJDRNJBFODGK-UHFFFAOYSA-N 2-(6-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-phenoxazin-10-ylethanone Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)CN1CC2=CC=C(O)C=C2CC1 ZLEJDRNJBFODGK-UHFFFAOYSA-N 0.000 description 1
- OXAJBQMFWOUKFK-UHFFFAOYSA-N 2-(7-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-phenoxazin-10-ylethanone Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)CN1CCC2=CC=C(O)C=C2C1 OXAJBQMFWOUKFK-UHFFFAOYSA-N 0.000 description 1
- PRGBGDMKVCZBKH-UHFFFAOYSA-N 2-(8-amino-3,4-dihydro-1h-isoquinolin-2-yl)-1-phenoxazin-10-ylethanone Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)CN1CCC(C=CC=C2N)=C2C1 PRGBGDMKVCZBKH-UHFFFAOYSA-N 0.000 description 1
- XVJITNIBPZSVSG-UHFFFAOYSA-N 2-(8-amino-3,4-dihydro-1h-isoquinolin-2-yl)-n-(2,2-diphenylethyl)acetamide Chemical compound C1C=2C(N)=CC=CC=2CCN1CC(=O)NCC(C=1C=CC=CC=1)C1=CC=CC=C1 XVJITNIBPZSVSG-UHFFFAOYSA-N 0.000 description 1
- CTLKHYHLUMUNNL-UHFFFAOYSA-N 2-(8-ethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-(3-phenyl-2,3-dihydro-1,4-benzoxazin-4-yl)ethanone Chemical compound C1C=2C(OCC)=CC=CC=2CCN1CC(=O)N(C1=CC=CC=C1OC1)C1C1=CC=CC=C1 CTLKHYHLUMUNNL-UHFFFAOYSA-N 0.000 description 1
- BGQLAOGLIPHUCC-UHFFFAOYSA-N 2-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-(2-methylsulfanylphenothiazin-10-yl)ethanone Chemical compound C1CC2=CC=CC(O)=C2CN1CC(=O)N1C2=CC=CC=C2SC2=CC=C(SC)C=C21 BGQLAOGLIPHUCC-UHFFFAOYSA-N 0.000 description 1
- SYHUYFXZECIUBE-UHFFFAOYSA-N 2-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-phenoxazin-10-ylethanone Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)CN1CCC(C=CC=C2O)=C2C1 SYHUYFXZECIUBE-UHFFFAOYSA-N 0.000 description 1
- ZDTJHLUKDRHCJJ-UHFFFAOYSA-N 2-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)-n-(4-hydroxyphenyl)-n-phenylacetamide Chemical compound C1=CC(O)=CC=C1N(C=1C=CC=CC=1)C(=O)CN1CC2=C(O)C=CC=C2CC1 ZDTJHLUKDRHCJJ-UHFFFAOYSA-N 0.000 description 1
- BEWKALWZRLUDJT-UHFFFAOYSA-N 2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-(1-methylpyrazolo[4,3-b][1,4]benzoxazin-9-yl)ethanone Chemical compound C1=NN(C)C2=C1OC1=CC=CC=C1N2C(=O)CN1CCC(C=CC=C2OC)=C2C1 BEWKALWZRLUDJT-UHFFFAOYSA-N 0.000 description 1
- PWAKUSPAIBNERE-UHFFFAOYSA-N 2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-(3-methyl-2,3-dihydro-1,4-benzoxazin-4-yl)ethanone Chemical compound CC1COC2=CC=CC=C2N1C(=O)CN1CCC(C=CC=C2OC)=C2C1 PWAKUSPAIBNERE-UHFFFAOYSA-N 0.000 description 1
- JSOJHKCVXMLIML-UHFFFAOYSA-N 2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-[3-(4-methoxyphenyl)-2,3-dihydro-1,4-benzoxazin-4-yl]ethanone Chemical compound C1=CC(OC)=CC=C1C1N(C(=O)CN2CC3=C(OC)C=CC=C3CC2)C2=CC=CC=C2OC1 JSOJHKCVXMLIML-UHFFFAOYSA-N 0.000 description 1
- ZYPCHABQMOZJJS-UHFFFAOYSA-N 2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-phenothiazin-10-ylethanone Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1C(=O)CN1CCC(C=CC=C2OC)=C2C1 ZYPCHABQMOZJJS-UHFFFAOYSA-N 0.000 description 1
- WLDVETGKHDMUNI-UHFFFAOYSA-N 2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-phenoxazin-10-ylpropan-1-one Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)C(C)N1CCC(C=CC=C2OC)=C2C1 WLDVETGKHDMUNI-UHFFFAOYSA-N 0.000 description 1
- FPQDLWTYYGPDCS-UHFFFAOYSA-N 2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-n',n'-diphenylacetohydrazide Chemical compound C1C=2C(OC)=CC=CC=2CCN1CC(=O)NN(C=1C=CC=CC=1)C1=CC=CC=C1 FPQDLWTYYGPDCS-UHFFFAOYSA-N 0.000 description 1
- WQLJPFSZWWMLSB-UHFFFAOYSA-N 2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-n,n-bis(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1N(C=1C=CC(OC)=CC=1)C(=O)CN1CC2=C(OC)C=CC=C2CC1 WQLJPFSZWWMLSB-UHFFFAOYSA-N 0.000 description 1
- JZFQAAQVKRLZHD-UHFFFAOYSA-N 2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-n,n-diphenylacetamide Chemical compound C1C=2C(OC)=CC=CC=2CCN1CC(=O)N(C=1C=CC=CC=1)C1=CC=CC=C1 JZFQAAQVKRLZHD-UHFFFAOYSA-N 0.000 description 1
- LZVWERPULIVCTO-UHFFFAOYSA-N 2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-n-(1-phenylethyl)acetamide Chemical compound C1C=2C(OC)=CC=CC=2CCN1CC(=O)NC(C)C1=CC=CC=C1 LZVWERPULIVCTO-UHFFFAOYSA-N 0.000 description 1
- OKKHUBIYCBBUFF-UHFFFAOYSA-N 2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-n-(2-phenoxyphenyl)acetamide Chemical compound C1C=2C(OC)=CC=CC=2CCN1CC(=O)NC1=CC=CC=C1OC1=CC=CC=C1 OKKHUBIYCBBUFF-UHFFFAOYSA-N 0.000 description 1
- PBKMDQPZWIHXRL-UHFFFAOYSA-N 2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethanamine Chemical compound C1CN(CCN)CC2=C1C=CC=C2OC PBKMDQPZWIHXRL-UHFFFAOYSA-N 0.000 description 1
- GLRUNADYXJDZKY-UHFFFAOYSA-N 2-(benzhydrylideneamino)oxy-1-(3,4-dihydro-1h-isoquinolin-2-yl)ethanone Chemical compound C1CC2=CC=CC=C2CN1C(=O)CON=C(C=1C=CC=CC=1)C1=CC=CC=C1 GLRUNADYXJDZKY-UHFFFAOYSA-N 0.000 description 1
- UWEKIEKWTHVHFC-UHFFFAOYSA-N 2-(benzhydrylideneamino)oxy-1-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethanone Chemical compound C1C=2C(OC)=CC=CC=2CCN1C(=O)CON=C(C=1C=CC=CC=1)C1=CC=CC=C1 UWEKIEKWTHVHFC-UHFFFAOYSA-N 0.000 description 1
- YVRWYILBACZNLR-UHFFFAOYSA-N 2-[(2,5-difluorophenyl)methyl]-3,4-dihydro-1h-isoquinolin-8-ol Chemical compound C1C=2C(O)=CC=CC=2CCN1CC1=CC(F)=CC=C1F YVRWYILBACZNLR-UHFFFAOYSA-N 0.000 description 1
- JWKSQXODXAYYRS-UHFFFAOYSA-N 2-[2,2-diphenylethyl-[2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-2-oxoethyl]amino]-1-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethanone Chemical compound C1C=2C(OC)=CC=CC=2CCN1C(=O)CN(CC(=O)N1CC2=C(OC)C=CC=C2CC1)CC(C=1C=CC=CC=1)C1=CC=CC=C1 JWKSQXODXAYYRS-UHFFFAOYSA-N 0.000 description 1
- VWVCDZKBMIMGSH-UHFFFAOYSA-N 2-[2-(dibenzylamino)ethyl]-3,4-dihydro-1h-isoquinolin-8-ol Chemical compound C1C=2C(O)=CC=CC=2CCN1CCN(CC=1C=CC=CC=1)CC1=CC=CC=C1 VWVCDZKBMIMGSH-UHFFFAOYSA-N 0.000 description 1
- WYIYXCYCQDAERE-UHFFFAOYSA-N 2-[4,4-bis(4-fluorophenyl)butyl]-1,3-dihydroisoindol-4-amine Chemical compound C1C=2C(N)=CC=CC=2CN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 WYIYXCYCQDAERE-UHFFFAOYSA-N 0.000 description 1
- WCDRWOCPMQSKIY-UHFFFAOYSA-N 2-[4,4-bis(4-fluorophenyl)butyl]-3,4-dihydro-1h-isoquinolin-8-ol Chemical compound C1C=2C(O)=CC=CC=2CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 WCDRWOCPMQSKIY-UHFFFAOYSA-N 0.000 description 1
- HOAYULJNLPMGSW-UHFFFAOYSA-N 2-chloro-1-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethanone Chemical compound C1CN(C(=O)CCl)CC2=C1C=CC=C2OC HOAYULJNLPMGSW-UHFFFAOYSA-N 0.000 description 1
- UVBXCNDFSWKPKY-UHFFFAOYSA-N 2-chloro-n-(2,2-diphenylethyl)acetamide Chemical compound C=1C=CC=CC=1C(CNC(=O)CCl)C1=CC=CC=C1 UVBXCNDFSWKPKY-UHFFFAOYSA-N 0.000 description 1
- FEHRVEAMFNFQHT-UHFFFAOYSA-N 2-chloro-n-(4,4-diphenylbutyl)acetamide Chemical compound C=1C=CC=CC=1C(CCCNC(=O)CCl)C1=CC=CC=C1 FEHRVEAMFNFQHT-UHFFFAOYSA-N 0.000 description 1
- MMUCAFWOXPWJJB-UHFFFAOYSA-N 2-chloro-n-[phenyl(pyridin-2-yl)methyl]acetamide Chemical compound C=1C=CC=NC=1C(NC(=O)CCl)C1=CC=CC=C1 MMUCAFWOXPWJJB-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
- XWAVPOFYNPXXEL-UHFFFAOYSA-N 2-phenylmethoxypropanoic acid Chemical compound OC(=O)C(C)OCC1=CC=CC=C1 XWAVPOFYNPXXEL-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- IZKIJEFWOGDDDB-UHFFFAOYSA-N 3,3-bis(4-fluorophenyl)propanoyl chloride Chemical compound C1=CC(F)=CC=C1C(CC(Cl)=O)C1=CC=C(F)C=C1 IZKIJEFWOGDDDB-UHFFFAOYSA-N 0.000 description 1
- KISZTEOELCMZPY-UHFFFAOYSA-N 3,3-diphenylpropylamine Chemical compound C=1C=CC=CC=1C(CCN)C1=CC=CC=C1 KISZTEOELCMZPY-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- RMRKTLOJIPPWQB-UHFFFAOYSA-N 3-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-phenoxazin-10-ylpropan-1-one Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)CCN1CCC(C=CC=C2O)=C2C1 RMRKTLOJIPPWQB-UHFFFAOYSA-N 0.000 description 1
- NRZGMSVUTJXKBL-UHFFFAOYSA-N 3-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-phenoxazin-10-ylpropan-1-one Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)CCN1CCC(C=CC=C2OC)=C2C1 NRZGMSVUTJXKBL-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 1
- BKQRBYFLQYHTCV-UHFFFAOYSA-N 3-phenyl-3,4-dihydro-2h-1,4-benzoxazine Chemical compound C1OC2=CC=CC=C2NC1C1=CC=CC=C1 BKQRBYFLQYHTCV-UHFFFAOYSA-N 0.000 description 1
- COYPLDIXZODDDL-UHFFFAOYSA-N 3h-benzimidazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N=CNC2=C1 COYPLDIXZODDDL-UHFFFAOYSA-N 0.000 description 1
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- MWALJJQSYJRMEI-UHFFFAOYSA-N 8-methoxy-3,4-dihydro-1h-isoquinoline-2-carbothioic s-acid Chemical compound C1CN(C(S)=O)CC2=C1C=CC=C2OC MWALJJQSYJRMEI-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000029197 Amphetamine-Related disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 208000033600 Arachnophobia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000036640 Asperger disease Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003628 Atonic seizures Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 238000006237 Beckmann rearrangement reaction Methods 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- GDGSVSHVIFCLSF-UHFFFAOYSA-N C(C1=CC=CC=C1)(C1=CC=CC=C1)NC(=S)N1CC2=CC=CC=C2CC1.C(C1=CC=CC=C1)(C1=CC=CC=C1)NC(CN1CC2=CC=CC=C2C1)=O Chemical compound C(C1=CC=CC=C1)(C1=CC=CC=C1)NC(=S)N1CC2=CC=CC=C2CC1.C(C1=CC=CC=C1)(C1=CC=CC=C1)NC(CN1CC2=CC=CC=C2C1)=O GDGSVSHVIFCLSF-UHFFFAOYSA-N 0.000 description 1
- PYMYFYVJCZJFQK-UHFFFAOYSA-N C1(=CC=CC=C1)C(CNC(CN1CC2=C(C=CC=C2CC1)OC)=O)C1=CC=CC=C1.N1C=NC2=C1C=CC(=C2)C(=O)N2CC1=CC=CC=C1CC2 Chemical compound C1(=CC=CC=C1)C(CNC(CN1CC2=C(C=CC=C2CC1)OC)=O)C1=CC=CC=C1.N1C=NC2=C1C=CC(=C2)C(=O)N2CC1=CC=CC=C1CC2 PYMYFYVJCZJFQK-UHFFFAOYSA-N 0.000 description 1
- AGCKLPHOLXZMAF-UHFFFAOYSA-N C1(=CC=CC=C1)C(CNCC(=O)N1CC2=C(C=CC=C2CC1)OC)C1=CC=CC=C1.C(C1=CC=CC=C1)(C1=CC=CC=C1)NCC(=O)N1CC2=C(C=CC=C2CC1)OC Chemical compound C1(=CC=CC=C1)C(CNCC(=O)N1CC2=C(C=CC=C2CC1)OC)C1=CC=CC=C1.C(C1=CC=CC=C1)(C1=CC=CC=C1)NCC(=O)N1CC2=C(C=CC=C2CC1)OC AGCKLPHOLXZMAF-UHFFFAOYSA-N 0.000 description 1
- GQZMCOVAFRLSTO-UHFFFAOYSA-N C1N(CC2=CC=CC=C12)CC(=O)NCC(C1=CC=CC=C1)C1=CC=CC=C1.FC1=CC=C(C=C1)C(N1CCN(CC1)C(CN1CC2=CC=CC=C2CC1)=O)C1=CC=C(C=C1)F Chemical compound C1N(CC2=CC=CC=C12)CC(=O)NCC(C1=CC=CC=C1)C1=CC=CC=C1.FC1=CC=C(C=C1)C(N1CCN(CC1)C(CN1CC2=CC=CC=C2CC1)=O)C1=CC=C(C=C1)F GQZMCOVAFRLSTO-UHFFFAOYSA-N 0.000 description 1
- KJXLRQPARPSQRU-UHFFFAOYSA-N C1N(CC2=CC=CC=C12)CC(=O)NCCC(C1=CC=CC=C1)C1=CC=CC=C1.C1N(CCC2=CC=CC=C12)CC(=O)NCC(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound C1N(CC2=CC=CC=C12)CC(=O)NCCC(C1=CC=CC=C1)C1=CC=CC=C1.C1N(CCC2=CC=CC=C12)CC(=O)NCC(C1=CC=CC=C1)C1=CC=CC=C1 KJXLRQPARPSQRU-UHFFFAOYSA-N 0.000 description 1
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010064012 Central pain syndrome Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010053398 Clonic convulsion Diseases 0.000 description 1
- 208000022497 Cocaine-Related disease Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000033001 Complex partial seizures Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
- 208000002603 Dopa-responsive dystonia Diseases 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018101 Generalised tonic-clonic seizures Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000034308 Grand mal convulsion Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101000620451 Homo sapiens Leucine-rich glioma-inactivated protein 1 Proteins 0.000 description 1
- 101000654356 Homo sapiens Sodium channel protein type 10 subunit alpha Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 208000030990 Impulse-control disease Diseases 0.000 description 1
- 206010021750 Infantile Spasms Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 208000006264 Korsakoff syndrome Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000007914 Labor Pain Diseases 0.000 description 1
- 208000035945 Labour pain Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000004552 Lacunar Stroke Diseases 0.000 description 1
- 102100022275 Leucine-rich glioma-inactivated protein 1 Human genes 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000007873 MPTP Poisoning Diseases 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000005903 Manganese Poisoning Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 206010027566 Micturition urgency Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- FHHKFKXGBHBMHI-UHFFFAOYSA-N N-(3,3-diphenylpropyl)-2-(7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl)acetamide methyl N-[2-(4-methoxyphenyl)ethyl]carbamate Chemical compound COC(NCCC1=CC=C(C=C1)OC)=O.C1(=CC=CC=C1)C(CCNC(CN1CC2=CC(=CC=C2CC1)OC)=O)C1=CC=CC=C1 FHHKFKXGBHBMHI-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 206010028923 Neonatal asphyxia Diseases 0.000 description 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010062501 Non-cardiac chest pain Diseases 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 206010052794 Panic disorder with agoraphobia Diseases 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 208000023339 Pervasive Child Development disease Diseases 0.000 description 1
- 206010034759 Petit mal epilepsy Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 238000006929 Pictet-Spengler synthesis reaction Methods 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010036312 Post-traumatic epilepsy Diseases 0.000 description 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 201000007527 Retinal artery occlusion Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 229910020008 S(O) Inorganic materials 0.000 description 1
- 238000006085 Schmidt reaction Methods 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010040703 Simple partial seizures Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 102100031374 Sodium channel protein type 10 subunit alpha Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010043647 Thrombotic Stroke Diseases 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
- 201000006791 West syndrome Diseases 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- BOTRWJSINNQPHK-UHFFFAOYSA-N [2-(2-oxo-2-phenoxazin-10-ylethyl)-1,3-dihydroisoindol-4-yl] methanesulfonate Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)CN1CC(C=CC=C2OS(=O)(=O)C)=C2C1 BOTRWJSINNQPHK-UHFFFAOYSA-N 0.000 description 1
- OMPQEQGADRBQMX-UHFFFAOYSA-N [2-(2-oxo-2-phenoxazin-10-ylethyl)-3,4-dihydro-1h-isoquinolin-8-yl] methanesulfonate Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)CN1CCC(C=CC=C2OS(=O)(=O)C)=C2C1 OMPQEQGADRBQMX-UHFFFAOYSA-N 0.000 description 1
- 208000028311 absence seizure Diseases 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229920002892 amber Polymers 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000002059 anti-epileptogenic effect Effects 0.000 description 1
- 150000003974 aralkylamines Chemical class 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 208000025748 atypical depressive disease Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- DZRJLJPPUJADOO-UHFFFAOYSA-N chaetomin Natural products CN1C(=O)C2(Cc3cn(C)c4ccccc34)SSC1(CO)C(=O)N2C56CC78SSC(CO)(N(C)C7=O)C(=O)N8C5Nc9ccccc69 DZRJLJPPUJADOO-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 201000006145 cocaine dependence Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 208000017004 dementia pugilistica Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- LZXCEBPGNFLHEQ-UHFFFAOYSA-N dibenzyl(2-chloroethyl)azanium;chloride Chemical compound Cl.C=1C=CC=CC=1CN(CCCl)CC1=CC=CC=C1 LZXCEBPGNFLHEQ-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- NWVNXDKZIQLBNM-UHFFFAOYSA-N diphenylmethylpiperazine Chemical compound C1CNCCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 NWVNXDKZIQLBNM-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical group FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 201000007186 focal epilepsy Diseases 0.000 description 1
- 239000012909 foetal bovine serum Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical compound O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- VWFFDQNEHSUZFR-UHFFFAOYSA-N n,n-dibenzyl-2-(3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1CC2=CC=CC=C2CN1CC(=O)N(CC=1C=CC=CC=1)CC1=CC=CC=C1 VWFFDQNEHSUZFR-UHFFFAOYSA-N 0.000 description 1
- YZOVUEGAVQZUAD-UHFFFAOYSA-N n,n-dibenzyl-2-(3,4-dihydro-1h-isoquinolin-2-yl)ethanamine Chemical compound C1CC2=CC=CC=C2CN1CCN(CC=1C=CC=CC=1)CC1=CC=CC=C1 YZOVUEGAVQZUAD-UHFFFAOYSA-N 0.000 description 1
- SQTWYPHUDSLZIC-UHFFFAOYSA-N n,n-dibenzyl-2-(7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1C2=CC(OC)=CC=C2CCN1CC(=O)N(CC=1C=CC=CC=1)CC1=CC=CC=C1 SQTWYPHUDSLZIC-UHFFFAOYSA-N 0.000 description 1
- VLHAEDVCSPYNPF-UHFFFAOYSA-N n,n-dibenzyl-2-(7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide;n,n-dibenzyl-2-(7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethanamine Chemical compound C1C2=CC(OC)=CC=C2CCN1CCN(CC=1C=CC=CC=1)CC1=CC=CC=C1.C1C2=CC(OC)=CC=C2CCN1CC(=O)N(CC=1C=CC=CC=1)CC1=CC=CC=C1 VLHAEDVCSPYNPF-UHFFFAOYSA-N 0.000 description 1
- WZOIOOTVRDOSRQ-UHFFFAOYSA-N n,n-dibenzyl-2-(7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethanamine Chemical compound C1C2=CC(OC)=CC=C2CCN1CCN(CC=1C=CC=CC=1)CC1=CC=CC=C1 WZOIOOTVRDOSRQ-UHFFFAOYSA-N 0.000 description 1
- WHMASYJPFPSSNI-UHFFFAOYSA-N n,n-dibenzyl-2-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1C=2C(O)=CC=CC=2CCN1CC(=O)N(CC=1C=CC=CC=1)CC1=CC=CC=C1 WHMASYJPFPSSNI-UHFFFAOYSA-N 0.000 description 1
- OVWIRORWDCWBCF-UHFFFAOYSA-N n,n-dibenzyl-2-chloroacetamide Chemical compound C=1C=CC=CC=1CN(C(=O)CCl)CC1=CC=CC=C1 OVWIRORWDCWBCF-UHFFFAOYSA-N 0.000 description 1
- MZTKOQHRPLOXEG-UHFFFAOYSA-N n,n-dibenzyl-3-chloropropanamide Chemical compound C=1C=CC=CC=1CN(C(=O)CCCl)CC1=CC=CC=C1 MZTKOQHRPLOXEG-UHFFFAOYSA-N 0.000 description 1
- IDWIIXLEYKWHRU-UHFFFAOYSA-N n-(2,2-diphenylethyl)-3,4-dihydro-1h-isoquinoline-2-carbothioamide Chemical compound C1CC2=CC=CC=C2CN1C(=S)NCC(C=1C=CC=CC=1)C1=CC=CC=C1 IDWIIXLEYKWHRU-UHFFFAOYSA-N 0.000 description 1
- PHWUWPBQGBNDQT-UHFFFAOYSA-N n-(2,2-diphenylethyl)-8-methoxy-3,4-dihydro-1h-isoquinoline-2-carbothioamide Chemical compound C1C=2C(OC)=CC=CC=2CCN1C(=S)NCC(C=1C=CC=CC=1)C1=CC=CC=C1 PHWUWPBQGBNDQT-UHFFFAOYSA-N 0.000 description 1
- PPNUTNYEAZUJNI-UHFFFAOYSA-N n-(3,3-diphenylpropyl)-2-(7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1C2=CC(OC)=CC=C2CCN1CC(=O)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 PPNUTNYEAZUJNI-UHFFFAOYSA-N 0.000 description 1
- RPQFYGXEMNXMQF-UHFFFAOYSA-N n-(3,3-diphenylpropyl)-2-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1C=2C(O)=CC=CC=2CCN1CC(=O)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 RPQFYGXEMNXMQF-UHFFFAOYSA-N 0.000 description 1
- QNYGGKCXCYDPGE-UHFFFAOYSA-N n-(3-benzhydryloxypropyl)-2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1C=2C(OC)=CC=CC=2CCN1CC(=O)NCCCOC(C=1C=CC=CC=1)C1=CC=CC=C1 QNYGGKCXCYDPGE-UHFFFAOYSA-N 0.000 description 1
- RAMNVBSGQOUAOZ-UHFFFAOYSA-N n-(3-carbazol-9-ylpropyl)-2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1CCCNC(=O)CN1CCC(C=CC=C2OC)=C2C1 RAMNVBSGQOUAOZ-UHFFFAOYSA-N 0.000 description 1
- ZMAZOFFWILCLKN-UHFFFAOYSA-N n-(4,4-diphenylbutyl)-2-(4-methoxy-1,3-dihydroisoindol-2-yl)acetamide Chemical compound C1C=2C(OC)=CC=CC=2CN1CC(=O)NCCCC(C=1C=CC=CC=1)C1=CC=CC=C1 ZMAZOFFWILCLKN-UHFFFAOYSA-N 0.000 description 1
- JNYJRYAUDPKPAZ-UHFFFAOYSA-N n-(4,4-diphenylbutyl)-2-(8-ethoxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1C=2C(OCC)=CC=CC=2CCN1CC(=O)NCCCC(C=1C=CC=CC=1)C1=CC=CC=C1 JNYJRYAUDPKPAZ-UHFFFAOYSA-N 0.000 description 1
- WSRZOKXVJQHGFZ-UHFFFAOYSA-N n-(4,4-diphenylbutyl)-2-[8-(methanesulfonamido)-3,4-dihydro-1h-isoquinolin-2-yl]acetamide Chemical compound C1C=2C(NS(=O)(=O)C)=CC=CC=2CCN1CC(=O)NCCCC(C=1C=CC=CC=1)C1=CC=CC=C1 WSRZOKXVJQHGFZ-UHFFFAOYSA-N 0.000 description 1
- MKFXNJZXTPMTKO-UHFFFAOYSA-N n-(9h-fluoren-9-yl)-2-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1NC(=O)CN1CCC(C=CC=C2O)=C2C1 MKFXNJZXTPMTKO-UHFFFAOYSA-N 0.000 description 1
- PJGFSNDWDQYLCA-UHFFFAOYSA-N n-(9h-fluoren-9-yl)-2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1NC(=O)CN1CCC(C=CC=C2OC)=C2C1 PJGFSNDWDQYLCA-UHFFFAOYSA-N 0.000 description 1
- HSJVLRVRHLKHSR-UHFFFAOYSA-N n-[2-(2-oxo-2-phenoxazin-10-ylethyl)-1,3-dihydroisoindol-4-yl]methanesulfonamide Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)CN1CC(C=CC=C2NS(=O)(=O)C)=C2C1 HSJVLRVRHLKHSR-UHFFFAOYSA-N 0.000 description 1
- COVZDQYWYUKRQG-UHFFFAOYSA-N n-[2-(3,4-dihydro-1h-isoquinolin-2-yl)ethyl]-3,3-diphenylpropan-1-amine Chemical compound C1CC2=CC=CC=C2CN1CCNCCC(C=1C=CC=CC=1)C1=CC=CC=C1 COVZDQYWYUKRQG-UHFFFAOYSA-N 0.000 description 1
- VIYOJRYGPIAKJW-UHFFFAOYSA-N n-[2-(7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]-3,3-diphenylpropan-1-amine Chemical compound C1C2=CC(OC)=CC=C2CCN1CCNCCC(C=1C=CC=CC=1)C1=CC=CC=C1 VIYOJRYGPIAKJW-UHFFFAOYSA-N 0.000 description 1
- BDQFXLMJTSDHKA-UHFFFAOYSA-N n-[2-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenoxazine-10-carboxamide Chemical compound C12=CC=CC=C2OC2=CC=CC=C2N1C(=O)NCCN1CCC(C=CC=C2O)=C2C1 BDQFXLMJTSDHKA-UHFFFAOYSA-N 0.000 description 1
- MUWIWXCKKIVUEV-UHFFFAOYSA-N n-[3,3-bis(4-fluorophenyl)propyl]-3-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)propanamide Chemical compound C1C=2C(OC)=CC=CC=2CCN1CCC(=O)NCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 MUWIWXCKKIVUEV-UHFFFAOYSA-N 0.000 description 1
- URIWSHJHIPQWIP-UHFFFAOYSA-N n-[3,3-bis(4-methoxyphenyl)propyl]-2-(3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1=CC(OC)=CC=C1C(C=1C=CC(OC)=CC=1)CCNC(=O)CN1CC2=CC=CC=C2CC1 URIWSHJHIPQWIP-UHFFFAOYSA-N 0.000 description 1
- YQZLQEAGQKTJPB-UHFFFAOYSA-N n-[3,3-bis(4-methoxyphenyl)propyl]-2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1=CC(OC)=CC=C1C(C=1C=CC(OC)=CC=1)CCNC(=O)CN1CC2=C(OC)C=CC=C2CC1 YQZLQEAGQKTJPB-UHFFFAOYSA-N 0.000 description 1
- BWAYVYUUDHPYIC-UHFFFAOYSA-N n-[3-(5-chloro-2-methylindol-1-yl)propyl]-2-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1CC2=CC=CC(O)=C2CN1CC(=O)NCCCN1C2=CC=C(Cl)C=C2C=C1C BWAYVYUUDHPYIC-UHFFFAOYSA-N 0.000 description 1
- VSPBYPUYAVFKTP-UHFFFAOYSA-N n-[bis(4-fluorophenyl)methyl]-2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1C=2C(OC)=CC=CC=2CCN1CC(=O)NC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VSPBYPUYAVFKTP-UHFFFAOYSA-N 0.000 description 1
- CZYFGZYVXMLAKU-UHFFFAOYSA-N n-benzhydryl-2-(3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1CC2=CC=CC=C2CN1CC(=O)NC(C=1C=CC=CC=1)C1=CC=CC=C1 CZYFGZYVXMLAKU-UHFFFAOYSA-N 0.000 description 1
- AWVPCOSQYYWQIX-UHFFFAOYSA-N n-benzhydryl-2-(4-methoxy-1,3-dihydroisoindol-2-yl)acetamide Chemical compound C1C=2C(OC)=CC=CC=2CN1CC(=O)NC(C=1C=CC=CC=1)C1=CC=CC=C1 AWVPCOSQYYWQIX-UHFFFAOYSA-N 0.000 description 1
- RTTPWPUNSUKONR-UHFFFAOYSA-N n-benzhydryl-2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-n-phenylacetamide Chemical compound C1C=2C(OC)=CC=CC=2CCN1CC(=O)N(C=1C=CC=CC=1)C(C=1C=CC=CC=1)C1=CC=CC=C1 RTTPWPUNSUKONR-UHFFFAOYSA-N 0.000 description 1
- CFRUNRIDFDXWAQ-UHFFFAOYSA-N n-benzhydryl-2-(8-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)acetamide Chemical compound C1C=2C(OC)=CC=CC=2CCN1CC(=O)NC(C=1C=CC=CC=1)C1=CC=CC=C1 CFRUNRIDFDXWAQ-UHFFFAOYSA-N 0.000 description 1
- PCKVTHWBTUTYBM-UHFFFAOYSA-N n-benzhydryl-3,4-dihydro-1h-isoquinoline-2-carbothioamide Chemical compound C1CC2=CC=CC=C2CN1C(=S)NC(C=1C=CC=CC=1)C1=CC=CC=C1 PCKVTHWBTUTYBM-UHFFFAOYSA-N 0.000 description 1
- DNYZBFWKVMKMRM-UHFFFAOYSA-N n-benzhydrylidenehydroxylamine Chemical compound C=1C=CC=CC=1C(=NO)C1=CC=CC=C1 DNYZBFWKVMKMRM-UHFFFAOYSA-N 0.000 description 1
- CKBJNHQOPRQBSF-UHFFFAOYSA-N n-benzyl-2-(3,4-dihydro-1h-isoquinolin-2-yl)-n-phenylacetamide Chemical compound C1CC2=CC=CC=C2CN1CC(=O)N(C=1C=CC=CC=1)CC1=CC=CC=C1 CKBJNHQOPRQBSF-UHFFFAOYSA-N 0.000 description 1
- DDAMHLYXZXYAMW-UHFFFAOYSA-N n-benzyl-2-(8-hydroxy-3,4-dihydro-1h-isoquinolin-2-yl)-n-phenylacetamide Chemical compound C1C=2C(O)=CC=CC=2CCN1CC(=O)N(C=1C=CC=CC=1)CC1=CC=CC=C1 DDAMHLYXZXYAMW-UHFFFAOYSA-N 0.000 description 1
- CFSKJDUGDLZDTI-UHFFFAOYSA-N n-benzyl-2-chloro-n-phenylacetamide Chemical compound C=1C=CC=CC=1N(C(=O)CCl)CC1=CC=CC=C1 CFSKJDUGDLZDTI-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 229940124707 pain therapeutics Drugs 0.000 description 1
- 230000001898 pallidal effect Effects 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 208000033300 perinatal asphyxia Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 239000002728 pyrethroid Substances 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 208000022934 urinary frequency Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/10—Quaternary compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present invention relates to inhibitors of the subtype of mammalian sodium channels known as Na v 1.8 or sensory neurone specific (SNS) channels.
- the Na v 1.8 channel is a 1,957 amino acid tetrodotoxin-insensitive voltage-gated sodium channel.
- the sodium channel, nucleic acid sequences coding for the channel, vectors, host cells and methods of identifying modulators, are taught in US-A- 6451554.
- the ⁇ -subunit gene corresponding to this ion channel is referred to as SCN10A.
- the channel is described in more detail in Akopian et al, (1996), 379, 257-262.
- X is -N- or -CH-; n is from 0 to 3; each Ri is the same or different and is a hydroxy, amino, halogen, C ⁇ -C 6 alkyl, C ⁇ -C 6 haloalkyl, C ⁇ -C 6 alkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 alkynyloxy, - haloalkoxy, C ⁇ -C 6 alkylthio, C ⁇ -C 6 haloalkylthio, (C ⁇ C 6 alkyl)amino or di(C ⁇ -C 6 alkyl)amino group; p is 0 or 1 ; R is cyano, -NR / -CO-(C 1 -C 4 alkyl), -NR-S(O) 2 -(C 1 -C 4 alkyl), -CO 2 H, - S(O) 2 OH, -CO 2 -(C C 4 alkyl), -O-S
- L is a direct bond or a -C ⁇ alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl moiety and A is Ce- o aryl, C 3 -C 6 carbocyclyl, a 5- to 10- membered heteroaryl group or a 5- to 10- membered heterocyclic group,
- the compounds of the invention are compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein: X is -N- or -CH-; n is from 0 to 3; p is 0; each R ⁇ is the same or different and is a hydroxy, amino, halogen, C ⁇ -C 6 alkyl, C ⁇ -C 6 haloalkyl, C ⁇ -C 6 alkoxy, C ⁇ -C 6 haloalkoxy, Ci-C ⁇ alkylthio, C ⁇ -C 6 haloalkylthio, (QC ⁇ alkyl)amino or di(C 1 -C 6 alkyl)amino group; m is 1, 2 or 3; and R is either
- L is a direct bond or a CrC 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl moiety and A is C ⁇ -Cio aryl, C 3 -C 6 carbocyclyl, a 5- to 10- membered heteroaryl group or a 5- to 10- membered heterocyclic group,
- a d-C 6 alkyl group or moiety is a linear or branched alkyl group or moiety containing from 1 to 6 carbon atoms, such as C 1 -C 4 alkyl group or moiety, for example methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl and t-butyl.
- a divalent alkyl moiety (or alkylene moiety) can be attached via the same carbon atom, by adjacent carbon atoms or by non-adjacent carbon atoms.
- a C 2 -C 6 alkenyl group or moiety is a linear or branched alkenyl group or moiety containing from 2 to 6 carbon atoms, such as a C 2 -C 4 alkenyl group or moiety, for example ethenyl, propenyl and butenyl.
- an alkenyl group or moiety is saturated except for one double bond.
- a divalent alkenyl moiety (or alkenylene moiety) can be attached via the same carbon atoms, via adjacent carbon atoms or via non-adjacent carbon atoms.
- a C 2 -C 6 alkynyl group or moiety is a linear or branched alkynyl group or moiety containing from 2 to 6 carbon atoms, such as a C -C alkynyl group or moiety, for example ethynyl, propynyl and butynyl.
- a C -C alkynyl group or moiety for example ethynyl, propynyl and butynyl.
- an alkynyl group or moiety is saturated except for one triple bond.
- a divalent alkynyl moiety (or alkynylene moiety) can be attached via the same carbon atom, via adjacent carbon atoms or via non-adjacent carbon atoms.
- a C 6 -do aryl group or moiety is typically a phenyl or naphthyl group or moiety. It is preferably a phenyl group or moiety.
- a 5- to 10- membered heteroaryl group is a 5- to 10- membered aromatic ring, such as a 5- or 6- membered ring, containing at least one heteroatom, for example 1, 2 or 3 heteroatoms, selected from O, S and N.
- Examples include pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, furanyl, thienyl, imidazolyl, pyrazolidinyl, pyrrolyl, oxadiazolyl, isoxazyl, thiadiazolyl, thiazolyl and pyrazolyl groups.
- Thienyl, triazolyl, pyridyl, thiazolyl and imidazolyl groups are preferred.
- Pyrrolyl groups are also preferred.
- a halogen is typically chlorine, fluorine, bromine or iodine - and is preferably chlorine or fluorine.
- a said d-C 6 alkoxy group is typically a said d-C 6 alkyl group attached to an oxygen atom.
- a said d-C 6 alkylthio group is typically a said d-C 6 alkyl group attached to a thio group.
- a d-d haloalkyl group is typically a said d-C 6 alkyl group, for example a C ⁇ -C 4 alkyl group, substituted by one or more said halogen atoms. Typically, it is substituted by 1, 2 or 3 said halogen atoms.
- Preferred haloalkyl groups include perhaloalkyl groups such as -CX 3 wherein X is a said halogen atom.
- Particularly preferred haloalkyl groups are -CF 3 and -CC1 3 .
- a d-C 6 haloalkoxy group is typically a said d-C 6 alkoxy group, for example a d-C 4 alkoxy-group, substituted by one or more said halogen atoms. Typically, it is substituted by 1, 2 or 3 said halogen' atoms.
- Preferred haloalkoxy groups include perhaloalkoxy groups such as -OCX 3 wherein X is a said halogen atom.
- haloalkoxy groups are -OCF 3 and -OCCI 3 .
- a d-C 6 haloalkylthio group is typically a said C ⁇ -C 6 alkylthio group, for example a d-C 4 alkylthio group, substituted by one or more said halogen atoms. Typically, it is substituted by 1, 2 or 3 said halogen atoms.
- Preferred haloalkylthio groups include perhaloalkylthio groups such as -SCX wherein X is a said halogen atom.
- Particularly preferred haloalkylthio groups are -SCF 3 and
- a C 3 -C 6 carbocyclyl group or moiety is a non-aromatic saturated or unsaturated hydrocarbon ring, having from 3 to 6 carbon atoms.
- a saturated group i.e. a C 3 -C 6 cycloalkyl group.
- examples include cyclobutyl, cyclopentyl and cyclohexyl.
- a 5- to 10- membered heterocyclyl group or moiety is a non- aromatic, saturated or unsaturated C 5 -do carbocyclic ring in which one or more, for example 1, 2 or 3, of the carbon atoms are replaced by a moiety selected from N, O, S, S(O) and S(O) 2 .
- Preferably, only one carbon atom is replaced with a -S(O)- or -S(O) 2 - moiety.
- a 5- to 10- membered heterocyclyl group or moiety is a non-aromatic, saturated or unsaturated d-do carbocyclic ring in which one or more, for example 1, 2 or 3, of the carbon atoms are replaced by a heteroatom selected from N, O and S.
- Saturated heterocyclyl groups are preferred.
- suitable " heterocyclyl groups include piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, tetrahydrofuranyl, imidazolidinyl, thiazolidinyl, 1,4 dioxanyl, 1,3 dioxolanyl and homopiperidinyl groups.
- heterocyclyl groups include thiomorpholino, S-oxo-thiomorpholino and S,S-dioxo-thiomorpholino groups.
- Preferred heterocyclyl groups are piperidinyl, morpholinyl, piperazinyl and homopiperidinyl groups.
- Further preferred heterocyclyl groups are thiomorpholino, S-oxo-thiomorpholino and S,S-dioxo-thiomorpholino groups.
- a said aryl, carbocyclyl, heteroaryl or heterocyclyl group is fused to two cyclic moieties selected from phenyl rings and 5- to 6- membered heterocyclyl and heteroaryl groups
- said cyclic moieties are fused directly to the aryl, carbocyclyl, heteroaryl or heterocyclyl group.
- the two cyclic moieties are not fused together.
- 1 or 2 of the said substituents on an aryl, heteroaryl, carbocyclyl or heterocyclyl group are selected from -NH-CO-(C 1 -C 4 alkyl), -CO-(C -C 4 alkyl), -CO 2 -(d-C 4 alkyl), 5- or 6- membered heteroaryl, phenyl and -CHPh 2 substituents.
- the aryl, heteroaryl, heterocyclyl and carbocyclyl groups and moieties in the substituents R 1 ⁇ R 2 , R 3 and R 4 are unsubstituted or are substituted by 1, 2 or 3 substituents which are the same or different and are selected from halogen, C ⁇ -C 4 alkyl, hydroxy, amino, (C ⁇ -C 4 alkyl)amino, d-C alkoxy, d-C 4 haloalkyl, C ⁇ -C 4 haloalkoxy, C ⁇ -C 4 alkylthio, d-C 4 haloalkylthio, -NH-CO-(C ⁇ -C 2 alkyl), -CO- (d-C 2 alkyl), -CO 2 -(C !
- -C 2 alkyl 5- membered heteroaryl, phenyl and -CHPh 2 substituents, the phenyl and heteroaryl moieties in said substituents being unsubstituted or substituted by 1 or 2 further substituents selected from halogen atoms, d-C 2 alkyl groups, d-C 2 alkoxy groups and -NH-CO-(d-C 2 alkyl) groups.
- substituents are selected from halogen, d-C 4 alkyl, hydroxy, d-C 4 alkoxy, d-C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 4 alkylthio, d-C 4 haloalkylthio, phenyl and -CHPh 2 substituents, the phenyl moieties in said substituents being unsubstituted or substituted by 1 or 2 halogen atoms.
- the aryl, heteroaryl, heterocyclyl and carbocyclyl groups and moieties in the substituents R 1 ⁇ R 2 , R 3 and R 4 are unsubstituted or are substituted by 1 or 2 substituents which are the same or different and are selected from halogen, d- C alkyl, hydroxy, amino, d-C 2 alkoxy, d-C haloalkyl, d-C 2 haloalkoxy, d-C 2 haloalkylthio, -NH-CO-(d-C 2 alkyl), -CO-(d-C 2 alkyl), -CO 2 -(er-e 2 -alkyl); oxadiazolyl, phenyl and -CHPh 2 substituents, the oxadiazolyl and phenyl moieties in said substituents being unsubstituted or substituted by 1 or 2 further substituents selected from halogen atoms, methyl groups
- these preferred substituents are selected from halogen, d-d alkyl, hydroxy, d-C 2 alkoxy, d-C 2 haloalkyl, C ⁇ -C 2 haloalkoxy, C ⁇ -C 2 haloalkylthio, phenyl and -CHPh substituents, the phenyl moieties in said substituents being unsubstituted or substituted by 1 or 2 further substituents selected from fluorine and chlorine atoms.
- X is -CH-.
- n is 0 or 1.
- each R ⁇ is the same or different and is a hydroxy, amino, halogen, Cj-C alkyl, d-C haloalkyl, d-C alkoxy, C 2 -C alkenyloxy, C C haloalkoxy, Ci- C 4 alkylthio or d-C 4 haloalkylthio group.
- each Ri is the same or different and is a hydroxy, halogen, C ⁇ -C 4 alkyl, C 1 -C haloalkyl, d-C alkoxy, C ⁇ -C 4 haloalkoxy, d-C 4 alkylthio or d-C 4 haloalkylthio group.
- each Ri is the same or different and is C ⁇ -C 2 alkyl, C -C 3 alkenyloxy, amino, hydroxy or C 1 -C 2 alkoxy.
- each i is the same or different and is Cj-C 2 alkyl, hydroxy or d-C 2 alkoxy.
- R is cyano, -NH-CO-(C ⁇ -C 4 alkyl), -NH-S(O) 2 -(d-C 4 alkyl), -O-
- R is cyano, -NH-CO-CH 3 , -NH-S(O) 2 -CH 3 , -O-S(O) 2 -CH 3 , -N-[SO 2 -CH 3 ] 2 or -S(O) 2 OH.
- p is 0 and Ri is located meta to the fused heterocycle, or on the phenyl carbon atom nearest the N atom.
- the compound of formula (I) is typically a compound of formula
- each L moiety in the R substituent is the same or different and represents a direct bond or a d-C 6 alkyl moiety.
- each L is the same or different and represents a direct bond or a C 1 -C4 alkyl moiety, for example a methyl, ethyl or propyl moiety, for example -CH(CH 3 )- or -CH 2 -CH(CH 3 )-.
- each L 7 moiety in the R 2 substituent is the same or different and represents a d-d alkyl moiety, preferably a d-C 4 alkyl moiety, for example a methyl, ethyl or propyl moiety, for example -CH(CH 3 )- or -CH 2 -CH(CH 3 )-.
- each A moiety in the R 2 substituent is the same or different and represents a C -do aryl, C 3 -C 6 cycloalkyl, 5- or 6- membered heterocyclyl or 5- or 6- membered heteroaryl group, which group is (a) unsubstituted or substituted by 1, 2 or 3 substituents selected from C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, halogen, hydroxy, amino, (C 1 -C 4 alkyl)amino, di(d-C 4 alkyl)amino, C 1 -C4 alkoxy, C ⁇ -C 4 haloalkoxy, C ⁇ -C 4 alkylthio, d-C 4 haloalkylthio, -NH-CO-(d-C 2 alkyl), phenyl and halophenyl substituents and (b) optionally fused to one or two cyclic moieties selected from phenyl rings and 5-
- each A moiety in the R 2 substituent is the same or different and represents a C 6 -do aryl, C 3 -C 6 cycloalkyl, 5- or 6- membered heterocyclyl or 5- or 6- membered heteroaryl group, which group is (a) unsubstituted or substituted by 1, 2 or 3 substituents selected from C 1 -C4 alkyl, C 1 -C4 haloalkyl, halogen, hydroxy, d-d alkoxy, C 1 -C 4 haloalkoxy, C 1 -C 4 alkylthio, C 1 -C 4 haloalkylthio, phenyl and halophenyl substituents and (b) optionally fused to one or two cyclic moieties selected from phenyl rings and 5- to 6- membered heterocyclyl or heteroaryl groups.
- each A moiety in the R 2 substituent is typically the same or different and is a phenyl, thienyl, triazolyl, pyridyl, pyrrolyl, pyrrolidinyl, 4-H-pyranyl, cyclopentyl, imidazolyl, thiazolyl or piperidyl group which is (a) unsubstituted or substituted by one or two substituents selected from halogen, d-C 2 haloalkyl, C ⁇ -C 2 haloalkoxy, C ⁇ -C 2 haloalkylthio, phenyl, d-d alkyl, d-C 2 alkoxy, amino, hydroxy and -NH-CO-(d-C 2 alkyl) groups and (b) optionally fused to one or two cyclic moieties selected from phenyl rings and 5- to 6- membered heteroaryl moieties.
- each A moiety in the R 2 substituent is the same or different and is a phenyl, thienyl, triazolyl, pyridyl, cyclopentyl, imidazolyl, hiazolyl or piperidyl group which is (a) unsubstituted or substituted by one or two substituents selected from halogen, d-C 2 haloalkyl, d-C 2 haloalkoxy, d- haloalkylthio, phenyl, d-d alkyl, d-C 2 alkoxy and hydroxy groups and (b) optionally fused to one or two cyclic moieties selected from phenyl rings and 5- to 6- membered heteroaryl moieties.
- each A moiety in the R 2 substituent is a phenyl, thienyl, triazolyl, pyridyl, fluorenyl, thiazolyl, tetrahydroisoquinolinyl, 9H-carbazolyl, indolinyl, 9H- xanthenyl or benzimidazolyl group, which group is unsubstituted or substituted by one or two substituents selected from halogen, d-C 2 alkyl, hydroxy, amino, d-C 2 alkoxy, d-C 2 haloalkyl, d-C 2 haloalkoxy, d-C 2 haloalkylthio, -NH-CO-CH 3 and phenyl substituents.
- each A moiety is a phenyl, thienyl, triazolyl, pyridyl, fluorenyl, thiazolyl, tetrahydroisoquinolinyl or benzimidazolyl group, which group is unsubstituted or substituted by one or two substituents selected from halogen, d-d alkyl, hydroxy, d-C 2 alkoxy, C ⁇ -C 2 haloalkyl, C ⁇ -C 2 haloalkoxy, C ⁇ -C haloalkylthio and phenyl substituents.
- each R substituent in each -CR(A) 2 moiety is the same or different and is hydrogen or methyl.
- each Het moiety in the R 2 substituent is -O-, -S- or -NR 7 - wherein R 7 is hydrogen, d-C alkyl, phenyl or -(C ⁇ -C alkyl)-phenyl. More preferably, each Het moiety in the R 2 substituent is -O- or -NR 7 - wherein R 7 is hydrogen, C ⁇ -C 4 alkyl or benzyl.
- the heteroaryl or heterocyclyl group is typically (a) monocyclic, (b) fused to one or two phenyl rings or (c) a morpholino group which is fused to a phenyl ring and to a lH-pyrazolyl group.
- R 3 and R 4 together with the N atom to which they are attached, form a heterocycle, they form a 5- to 7- membered heterocyclyl group.
- morpholino thiomorpholino, S-oxo-thiomorpholino, S,S- dioxo-thiomorpholino, pyrrolidinyl, piperazinyl or homopiperidinyl ring which is (a) optionally fused to one or two cyclic moieties selected from phenyl rings and 5- to 6- membered heteroaryl rings, and (b) unsubstituted or substituted by 1 or 2 substituents selected from C 1 -C 4 alkyl, d-C 4 haloalkyl, d-C 4 alkoxy, C 1 -C 4 alkylthio, halogen, phenyl, -CHPh 2 , -CO-(C ⁇ -C 2 alkyl), -CO 2 -(d-C 2 alkyl) arid - to 6- membered ' heteroaryl substituents, the phenyl and heteroaryl moieties in said substituents being
- R 3 and R 4 together with the N atom to which they are attached, form a heterocycle, they form a morpholino, piperazinyl or homopiperidinyl ring which is (a) unsubstituted or substituted by 1 or 2 substituents selected from C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, halogen, phenyl and -CHPh 2 substituents, the phenyl moieties in said substituents being unsubstituted or substituted by 1 or 2 halogen atoms and (b) optionally fused to one or two phenyl rings.
- R 3 represents hydrogen, d-d alkyl, phenyl, -(d-d alkyl)-phenyl or -(d-C 4 alkyl)-CHPh 2 . More typically, when R 3 and R 4 do not together form a heterocycle, R 3 represents hydrogen, C1-C4 alkyl, -(d-C 4 alkyl)-phenyl or -(C1-C4 alkyl)-CHPh 2 .
- the phenyl moieties in R 3 are unsubstituted or substituted by a hydroxy group. More preferably, R 3 is unsubstituted.
- R 3 represents hydrogen, d- alkyl or an unsubstituted benzyl, phenyl, hydroxyphenyl or -(C1-C2 alkyl)-CHPh 2 group. Most preferably R 3 represents hydrogen, d- alkyl or an unsubstituted benzyl or -(C ⁇ -C 2 ' alkyl)-CHPh 2 group.
- R 4 represents d-d alkyl, A, -(d-C 4 alkyl)-A, -(CH 2 ) m -CH(A) 2 , -CH[(CH 2 ) m A] 2 , -(CH 2 ) m -CO-A, -(CH 2 ) m -O-CH(A) 2 , -(CH 2 ) m -S-CH(A) 2 , . -(CH 2 ) m -S(O)-CH(A) 2 , -(CH 2 ) m -S(O) 2 -
- R 4 represents C 1 -C 4 alkyl, A, -(d-C alkyl)-A, -(CH 2 ) m -CH(A) 2 , -CH[(CH 2 ) m A] 2 or -(CH 2 ) m -CO-A wherein each A is the same or different and is as defined above and m is 0, 1, 2, 3 or 4.
- the A moieties in the 4 substituent are (a) unsubstituted or substituted by 1 or 2 substituents selected from d-C alkyl, C 1 -C 4 alkoxy, halogen, hydroxy, amino, C ⁇ -C 2 haloalkyl, d-C 2 haloalkoxy and d-C 2 haloalkylthio substituents and (b) monocyclic or fused to 1 or 2 phenyl rings.
- the A moieties in the R4 substituent are (a) unsubstituted or substituted by 1 or 2 substituents selected ⁇ from d-C alkyl; Cf-C alkoxy, halogen, d-C 2 haloalkyl, d-C 2 haloalkoxy and C ⁇ -C 2 haloalkylthio substituents and (b) monocyclic or fused to 1 or 2 phenyl rings.
- R- 4 represents C1-C 4 alkyl, fluorenyl, phenyl, pyridyl, -(C 1 -C 4 alkyl)-phenyl, -(C 1 -C 4 alkyl)-(5- to 6- membered heteroaryl), -(CH 2 ) m -(9H-carbazolyl), -(CH 2 ) m -indolinyl, -(CH 2 ) m -(9H-xanthenyl), -(CH 2 ) m -O-CHA 7 A 777 , -(CH 2 ) m -S-CHA 7 A 777 , -(CH 2 ) m -S(O)- CHA /7 A / , -(CH 2 ) m -S(O) 2 -CHA A 777 , -NH-CO-N(phenyl) 2
- a phenyl ring for example a tetrahydroisoquinoline group
- the cyclic moieties in said preferred R 4 groups being unsubstituted or substituted by a halogen atom, d-C 2 alkyl, hydroxy, amino or Cj-C 2 alkoxy group.
- R 4 represents d-C alkyl, fluorenyl, -(d-C alkyl)-phenyl, -(d-d alkyl)-(5- to 6- membered heteroaryl), -(CH 2 ) m -CHA 7 A 777 wherein m is 0, 1, 2 or 3 and A 77 and A 777 are the same or different and each represent phenyl or a 5- or 6- membered heteroaryl group, -CH[(CH 2 ) n Ph] 2 wherein n is 0, 1 or 2, or -(CH 2 ) p -CO-R wherein p is 1, 2 or 3 and R is a 5- or 6- membered heterocyclic group fused to a phenyl ring, for example a tetrahydroisoquinoline group, the cyclic moieties in said most preferred R 4 groups being unsubstituted or substituted by a halogen
- A is monocyclic. More typically, A is a monocyclic phenyl or 5- to 6- membered heteroaryl group.
- L is d-d alkyl and A is a phenyl or 5- or 6- membered heteroaryl group, which group is unsubstituted or substituted by 1, 2 or 3 substituents selected from C1-C 4 alkyl, C ⁇ -C 4 haloalkyl, halogen, hydroxy, d-C 4 alkoxy, d-C 4 haloalkoxy, d-C alkylthio, d-C 4 haloalkylthio, phenyl and halophenyl substituents.
- R is defined according to option (a)
- it is a -(d-C alkyl)- phenyl group, for example benzyl, or a -(C 1 -C 4 alkyl)-(5- to 6- membered heteroaryl) group, for example -CH 2 -thienyl or -CH 2 -triazolyl, the phenyl and heteroaryl
- R 2 is defined according to option (b), it is -L-CR(A) 2 wherein R and A are as defined above.
- L is d-C 4 alkyl
- R is hydrogen or methyl and each A is the same or different and is a phenyl group which is unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C ⁇ -C 2 haloalkyl, d-C 2 alkyl, -NH-CO-CH 3 and hydroxy substituents.
- L is d-d alkyl
- R is hydrogen or methyl and each A is the same or different and is a phenyl group which is unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, d-C 2 haloalkyl, d-C 2 alkyl and hydroxy substituents.
- L 7 is C -C alkyl
- Het is O, NH or -N(benzyl)-
- L is other than a direct bond. More typically, L is C ⁇ -C 6 alkyl.
- R 2 when R 2 is defined according to option (d), it is typically -L-CO- NR 3 R More typically, when R 2 is defined according to option (d), R 2 is -(CH 2 ) q - CO-lS ⁇ E-aR- wherein q is from 1 to 4, and is preferably 1 or 2, and R 3 and R 4 are as defined above.
- R 2 is defined according to option (d), either (i) R 3 and R 4 , together with the N atom to which they are attached, form a 5- to 7- membered heterocyclyl group or (ii) R 3 represents hydrogen, - alkyl, phenyl or -(d-d alkyl)- ⁇ henyl and R 4 represents - alkyl, A, -(C 1 -C 4 alkyl)-A, -(CH 2 ) m -CH(A) 2 , -CH[(CH 2 ) m A] 2 , -(CH 2 ) m -O-CH(A) 2 , -(CH 2 ) m -S-CH(A) 2 , -(CH 2 ) m -S(O)-CH(A) 2 , -(CH 2 ) m -S(O) 2 -CH(A) 2 , -(CH 2 ) m -S(O) 2 -CH(
- R 2 is defined according to option (d), either (i) R 3 and R 4 , together with the N atom to which they are attached, form a 5- to 7- membered heterocyclyl group or (ii) R 3 represents hydrogen, C1-C4 alkyl or -(C 1 -C 4 alkyl)- phenyl and R- 4 represents d-C alkyl, A, -(d-C alkyl)-A, -(CH 2 ) m -CH(A) 2 or - CH[(CH 2 ) m A] 2 wherein each A is the same or different and is as defined above and m is 0, 1, 2, 3 or 4.
- -More preferably, when -R 2 is defined according- to option (d) either (i) R 3 -and- • R- 4 , together with the N atom to which they are attached, form a morpholino, thiomorpholino, S-oxo-thiomorpholino, S,S-dioxo-thiomorpholino, pyrrolidinyl, piperazinyl or homopiperdinyl ring which is (a) optionally fused to 1 or 2 cyclic moieties selected from phenyl rings and 5- to 6- membered heteroaryl rings and (b) unsubstituted or substituted by 1 or 2 substituents selected from d-C 4 alkyl, d-C 4 haloalkyl, d-C 4 alkoxy, d-C alkylthio, halogen, phenyl, -CHPh 2 , -CO-(C ⁇ -C 2 alkyl), -CO 2 -(d-
- CHA 7/ A 777 -(CH 2 ) m -S(O)-CHA 77 A 777 , -(CH 2 )m-S(O) 2 -CHA 7 A 777 , -NH-CO-N(phenyl) 2 , -N(phenyl) 2 or -A 7 -O-A 777 , wherein m is 0, 1, 2 or 3, A 77 and A 777 are the same or different and each represent phenyl or a 5- or 6- membered heteroaryl group, and n is 0, 1 or 2, the cyclic moieties in these groups being unsubstituted or substituted by a halogen atom, d-C 2 alkyl, hydroxy, amino or d-C 2 alkoxy group.
- R is defined according to option (d) either (i) R 3 and R 4 , together with the N atom to which they are attached, form a morpholino, piperazinyl or homopiperdinyl ring which is (a) unsubstituted or substituted by 1 or 2 substituents selected from - alkyl, C1-C4 haloalkyl, halogen, phenyl and -CHPh 2 substituents, the phenyl moieties in said substituents being unsubstituted or substituted by 1 or 2 halogen atoms and (b) optionally fused to one or two phenyl rings or (ii) R 3 represents hydrogen, d-C 4 alkyl or an unsubstituted benzyl group and R 4 represents C 1 -C 4 alkyl, fluorenyl, -(C 1 -C4 alkyl)-phenyl, -(C ⁇ -C 6 alkyl)-(5- to 6-
- R 3 and f are n as defined" above.
- A is a said C 6 -do aryl group.
- R 2 is defined according to option (f) it is -CO-A 7 .
- R 2 is defined according to option (f) it is -CO-L-CH(A) 2 or -CO-L- A, wherein L is as defined above and each A is the same or different and is as defined above.
- R 2 when R 2 is defined according to option (f), it is -CO-CH 2 -CH(R) 2 or -CO-R 7 , wherein each R is the same or different and is a phenyl or halophenyl moiety and R 7 is a benzimidazolyl group.
- R 2 when R 2 is defined according to option (h), L 7 is d- alkyl.
- R is H.
- R3 and R4 together with the N atom to which they are attached, form a phenothiazine or phenoxazine group or (ii) R 3 is hydrogen and R t is -(CH 2 ) m -CHA 7 A 777 or -A 7 -O-A 7 / wherein m is 0, 1, 2 or 3 and A 77 and A 777 are the same or different and each represent phenyl or a 5- to 6-membered heteroaryl group.
- a 77 and A 777 are both phenyl.
- Preferred compounds of formula (I) are those in which: X is -N- or -CH-; m is 1, 2 or 3; each Ri is the same or different and is a hydroxy, amino, halogen, d-C 4 alkyl, C 1 -C 4 haloalkyl, d-C 4 alkoxy, C ⁇ -C 4 haloalkoxy, C 2 -C 4 alkenyloxy d-C 4 alkylthio, or d-d haloalkylthio group; p is 0 or 1; R is cyano, -NH-CO-(C ⁇ -C 4 alkyl), -NH-S(O) 2 -(C C 4 alkyl), -O-S(O) 2 -(d- C 4 alkyl), -S(O) 2 -OH or -N[S(O) 2 -(d-C 4 alkyl] 2 ; and - R 2 is either
- a 7 or -CS-A 7 is a said d-Cio aryl group.
- Further preferred compounds of formula (I) are those in which X is -CH-; - p is 0; _ • ⁇ m is 1, 2 or 3; each Ri is the same or different and is a hydroxy, halogen, C 1 -C 4 alkyl, d- haloalkyl, d-d alkoxy, C 1 -C 4 haloalkoxy, d-d alkylthio, or d-d haloalkylthio group; and - R 2 is either
- L is a direct bond or a C ⁇ -C 6 alkyl moiety and A is a C 6 -do aryl, d-C 6 cycloalkyl, 5- or 6- membered heterocyclyl or 5- or 6- membered heteroaryl group
- -L-CR(A) 2 or -L-CH C(A) 2 wherein R is hydrogen or d-C 4 alkyl
- L is as defined above and each A is the same or different and is as defined above
- R 3 represents hydrogen, d-d alkyl, -(C 1 -C 4 alkyl)-phenyl or -(C1-C4 alkyl)-CHPh 2 and R4 represents d-d alkyl, A, -(d-C 4 alkyl)-A, -(CH 2 ) m -CH(A) 2 , -CH[(CH 2 ) m A] 2 or -(CH 2 ) m -CO- A wherein each A is the same or different and is as defined above and m is 0, 1, 2, 3 or 4,
- More preferred compounds of formula (I) are compounds wherein: X is -N- or -CH-; - n is O or l; each Rj is the same or different and is d-C 2 alkyl, hydroxy or d-C 2 alkoxy; p is 0 or 1 ; Ri 7 is cyano, -NH-CO-CH3, -NH-S(O) 2 -CH 3 , -O-S(O) 2 -CH 3 , -N[SO -CH 3 ] 2 or -S(O) 2 -OH; - m is 1, 2 or 3; and R is either
- L represents a direct bond or a C 1 -C4 alkyl moiety, for example a methyl, ethyl or propyl moiety
- A is a phenyl, thienyl, triazolyl, pyridyl, fluorenyl, thiazolyl, tetrahydroisoquinolinyl, 9H-carbazolyl, indolinyl, 9H- xanthenyl or benzimidazolyl group, which group is unsubstituted or ' " substituted ' by one.
- Phenothiazine-10-carboxylic acid [2-(8-hydroxy-3 ,4-dihydro- lH-isoquinolin-2- yl)-ethyl]-amide
- Phenothiazine-10-carboxylic acid [2-(6,7-dimethoxy-3,4-dihydro-lH- isoquinolin-2-yl)-ethyl]-amide 162. Phenothiazine-10-carboxylic acid [2-(8-methoxy-3,4-dihydro-lH-isoquinolin- 2-yl)-ethyl]-amide
- a pharmaceutically acceptable salt is a salt with a pharmaceutically acceptable acid or base.
- Pharmaceutically acceptable acids include both inorganic acids such as hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic or nitric acid and organic acids such as citric, fumaric, maleic, malic, ascorbic, succinic, tartaric, benzoic, acetic, methanesulfonic, ethanesulfonic,.
- benzenesulfonic or p-toluenesulfonic acid include alkali metal (e.g. sodium or potassium) and alkali earth metal (e.g. calcium or magnesium) hydroxides and organic bases such as alkyl amines, aralkyl amines or heterocyclic amines.
- the compounds of the invention can contain one or more chiral centres.
- the chemical structures depicted herein are intended to embrace all stereoisomers of the compounds shown, including racemic and non- racemic mixtures and pure enantiomers and/or diastereoisomers.
- Preferred compounds of the invention are optically active isomers.
- preferred compounds of formula (I) containing only one chiral centre include an R enantiomer in substantially pure form, an S enantiomer in substantially pure form and enantiomeric mixtures which contain an excess of the R enantiomer. or an excess of the S enantiomer.
- the compounds of formula (I) may be prepared by conventional routes, for example those set out in any of schemes 1 to 10 shown below.
- Compounds of formula (1) in which m is 2 and X, Rj, n and R are defined as above (reaction scheme 1) maybe prepared from compounds of formula (2) and compounds of formula (3) where X is a leaving group, typically chlorine, using standard methods such as reaction in the presence of a base, for example potassium carbonate.
- Compounds of formula (2) may be prepared from compounds of formula (4) by standard methods familiar to those skilled in the art such as reduction in the presence of platinum oxide. -Alternatively, compounds of formula (2) may be prepared from compounds of formula (5) and formaldehyde by standard methods such as the Pictet-Spengler cyclisation. Compounds of formula (4) are known compounds or may be prepared by standard methods such as cyclisation of compounds of formula (6) according to the published procedure (Bioorg. Med. Chem. 7 (1999) 2647-2666).
- Compounds of formula (1) in which m is 1 and X, Rj, n and R 2 are defined as above may be prepared from compounds of formula (2) and compounds of formula (3) where X is a leaving group, typically chlorine, using standard methods such as reaction in the presence of a base for example potassium carbonate. Typically the reaction is performed in a solvent such as methanol, tetrahydrofuran or acetonitrile at a temperature of 95°C.
- Compounds of formula (2) may be prepared from compounds of formula (7) where X is a leaving group, preferably bromine, by standard methods familiar to those skilled in the art such as alkylation in the presence of an amine.
- compounds of formula (2) can be prepared from compounds of formula (7) where X is OH converted into a better leaving group such as a mesylate under standard alkylating conditions familiar to those skilled in the art.
- Compounds of formula (7) may be prepared from dimethylaryl compounds (8) by bromination using a brominating reagent, for example N-bromosuccinimide.
- -Alcohols (9) may be prepared from acids (10) by standard methods such as reduction in the presence of lithium aluminium hydride.
- Compounds of formula (I) in which hi is 3 and X, Ri, n and R are defined as above may be prepared from compounds of formula (2) and compounds of formula (3) where X is a leaving group, typically chlorine, using standard methods such as reaction in the presence of a base for example potassium carbonate. Typically the reaction is performed in a solvent such as methanol, tetrahydrofuran or acetonitrile at a temperature of 95°C.
- Compounds of formula (2) where m is 3 may be prepared from compounds of formula (11 ) by reduction in the presence of a metal hydride for example lithium aluminium hydride.
- Compounds of formula (11) may be prepared from tetralones (12) by standard methods familiar to those skilled in the art such as the Schmidt reaction.
- compounds of formula (11) may be prepared from tetralones (12) by standard methods familiar to those skilled in the art such as the Beckmann rearrangement or further methods as outlined e.g. in Alicyclic Chemistry, (Martin Grossel, Oxford University Press).
- Tetralones (12) are either known compounds or can be prepared by analogy with known methods.
- R 2 is -L-A and L is other than a direct bond, or when R 2 is -L-CR(A) 2 , the reaction between the compounds of formulae (2) and (3) in schemes 1, 2 and 3 is typically performed in a solvent such as methanol, tetrahydrofuran or acetonitrile at a temperature of 80°C.
- R 2 is -L-A and L is a direct bond
- the reaction between the compounds of formulae (2) and (3) is typically effected by Buchwald coupling.
- X in the formula (3) is typically bromine or iodine.
- the compounds of formula (3) are known compounds, or may be prepared by known methods.
- compounds of formula (3) in which R 2 is -(CH 2 ) 2 - CH(A) 2 can be prepared by the reduction of compounds of formula (14) in the presence of a reducing agent such as lithium aluminium hydride followed by halogenation in the presence of a halogenating agent such as PBr 3 (reaction scheme 4).
- a reducing agent such as lithium aluminium hydride
- a halogenating agent such as PBr 3
- Compounds of formula (14) may be prepared from diarylethenylacids (15) by reduction in the presence of a reducing agent such as palladium.
- Diarylethenylacids may be prepared from ketones (16) by standard methods familiar to those skilled in the art such as Wittig reaction. Scheme 4
- R 2 is -L-CO-NR3R 4
- the reaction between the compounds of formulae (2) and (3) in schemes 1 to 3 is typically effected in the presence of a base for example triethylamine.
- a base for example triethylamine.
- the reaction is performed in a solvent such as methanol, tetrahydrofuran or acetonitrile at a temperature of 80°C.
- - - compounds of formula (1) wherein R 2 is -L-CS-NR 3 R- ⁇ may be prepared from compounds of formula (1) where R 2 is -L-CO-NR 3 R 4 by standard methods familiar to those skilled in the art such as sulphonation in the presence of Lawesson's reagent.
- a further method for preparing compounds of formula (1) wherein X, m, Ri and n are defined as above and R 2 is -CO-L-N B involves the reaction of amides (24) and amines (22) where X is a leavmg group, preferably chlorine, using standard methods such as reaction in the presence of a base for example triethylamine (reaction scheme 8). Typically the reaction is performed in a solvent such as methanol, tetrahydrofuran or acetonitrile at a temperature of 80°C.
- Amides (24) may be prepared from amines (2) and acids (23), wherein X 7 is Cl or OH, under standard amide coupling reaction conditions.
- R 2 is -CO- A 7
- the reaction between the compounds of formulae (2) and (3) in schemes 1 , 2 and 3 is typically effected in the presence of a coupling agent such as EDC/HOBT, HATU or HBTU.
- a coupling agent such as EDC/HOBT, HATU or HBTU.
- Compounds of formula (1) wherein R 2 is -CS-A 7 can, of course, be prepared from compounds of formula (1) where R 2 is -CO- A 7 by standard methods familiar to those skilled in the art such as reaction with Lawesson's reagent.
- reaction scheme 9 X and X 7 represent leaving groups, for example chlorine.
- Compounds of formulae (31) and (31 a) may be prepared from amines (2) and compounds of formulae (30) or (30a) under standard amide coupling conditions as previously described.
- the compounds ofthe invention are found to be inhibitors of sensory neurone specific sodium channels.
- the compounds ofthe invention are therefore therapeutically useful.
- the present invention provides a compound of the formula (I), as defined above, or a pharmaceutically acceptable salt thereof, for use in the treatment ofthe human or animal body.
- a pharmaceutical composition comprising a compound ofthe formula (I), as defined above, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
- Said pharmaceutical composition typically contains up to 85 wt% of a compound ofthe invention. More typically, it contains up to 50 wt% of a compound ofthe invention.
- Preferred pharmaceutical compositions are sterile and pyrogen free.
- compositions provided by the invention typically contain a compound ofthe invention which is a substantially pure optical isomer.
- the compounds ofthe invention may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules.
- Preferred pharmaceutical compositions ofthe invention are compositions suitable for oral administration, for example tablets and capsules. Compositions suitable for oral administration may, if required, contain a colouring or flavoring agent.
- a said capsule or tablet comprises from 5 to 500 mg, preferably 10 to 500 mg, more preferably 15 to 100 mg, of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
- the compounds ofthe invention may also be admimstered parenterally, whether subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques.
- the compounds may also be administered as suppositories.
- One preferred route of administration is inhalation.
- the major. advantages of inhaled medications are their direct delivery to the area of rich blood supply in comparison to many medications taken by oral route. Thus, the absorption is very rapid as the alveoli have an enormous surface area and rich blood supply and first pass metabolism is bypassed.
- Preferred pharmaceutical compositions ofthe invention therefore include those suitable for inhalation.
- the present invention also provides an inhalation device containing such a pharmaceutical composition.
- said device is a metered dose inhaler (MDI), which contains a pharmaceutically acceptable chemical propellant to push the medication out ofthe inhaler.
- said propellant is a fluorocarbon.
- Further preferred inhalation devices include nebulizers. Nebulizers are devices capable of delivering fine liquid, mists of medication through a "mask" that fits over the nose and mouth, using air or oxygen under pressure. They are frequently used to treat those with asthma who cannot use an inhaler, including infants, young children and acutely ill patients of all ages. Said inhalation device can also be, for example, a rotary inhaler or a dry powder inhaler, capable of delivering a compound ofthe invention without a propellant.
- said inhalation device contains a spacer.
- a spacer is a device which enables individuals to inhale a greater amount of medication directly into the lower airways, where it is intended to go, rather than into the throat. Many spacers fit on the end of an inhaler; for some, the canister of medication fits into the device. Spacers with withholding'ch ' ambers and one-way valves prevent medication from escaping into the air. Many people, especially young children and the elderly, may have difficulties coordinating their inhalation with the action necessary to trigger a puff from a metered dose inhaler. For these patients, use of a spacer is particularly recommended. -Another preferred route of administration is intranasal administration.
- the nasal cavity's highly permeable tissue is very receptive to medication and absorbs it quickly and efficiently, more so than drugs in tablet form.
- Nasal drug delivery is less painful and invasive than injections, generating less anxiety among patients. Drugs can be delivered nasally in smaller doses than medication delivered in tablet form. By this method absorption is very rapid and first pass metabolism is bypassed, thus reducing inter-patient variability.
- Nasal delivery devices further allow medication to be administered in precise, metered doses.
- the pharmaceutical compositions of the invention are typically suitable for intranasal administration. Further, the present invention also provides an intranasal device containing such a pharmaceutical composition. A further preferred route of administration is transdermal administration.
- the present invention therefore also provides a transdermal patch containing a compound ofthe invention, or a pharmaceutically acceptable salt thereof. Also preferred is sublingual administration.
- the present invention therefore also provides a sub- lingual tablet comprising a compound ofthe invention or a pharmaceutically acceptable salt thereof.
- a compound ofthe invention is typically formulated for administration with a pharmaceutically acceptable carrier or diluent.
- solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g.
- binding agents e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone
- disaggregating agents e.g. starch, alginic acid, alginates or sodium starch glycolate
- dyesruffs effervescing mixtures
- sweeteners effervesc
- Liquid dispersions for oral administration may be syrups, emulsions and suspensions.
- the syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
- Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
- the suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable, carrier, e.g.
- sterile water olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.
- Solutions for injection or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.
- the compounds ofthe present invention are therapeutically useful in the treatment or prophylaxis of conditions involving sodium ion flux through a sensory neurone specific (SNS) channel of a sensory neurone.
- SNS sensory neurone specific
- Said condition may be one of hypersensitivity for example resulting from a concentration of SNS channels at the site of nerve injury or in axons following nerve injury, or may be sensitisation ofthe neurone for example at sites of inflammation as a result of inflammatory mediators.
- Said compounds ofthe invention are therefore most preferred for their use in the treatment or prophylaxis of any condition involving hypersensitivity or sensitisation of a sensory neurone specific (SNS) channel of a sensory neurone.
- SNS sensory neurone specific
- the present invention also provides the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment or prophylaxis of a condition involving sodium ion flux through a sensory neurone specific (SNS) channel of a sensory neurone, more specifically hypersensitivity of a sensory neurone or sensitisation of a sensory neurone specific (SNS) channel of a sensory neurone.
- SNS sensory neurone specific
- SNS sensory neurone specific
- the term treatment in this context is deemed to cover any effect from a cure of said condition to alleviation of any or all ofthe symptoms.
- the compounds ofthe invention may, where appropriate, be used prophylactically to reduce the incidence or severity of said conditions.
- SNS channels are present and believed to be involved, include pain, for example chronic and acute pain, hypersensitivity disorders such as bladder dysfunction and bowel disorders which may or may not also have associated pain, and demyelinating diseases.
- SNS sodium channels are known to mediate pain transmission.
- the compounds ofthe invention are therefore used as analgesic agents.
- SNS specific sodium channels have been identified as being particularly important in the transmission of pain signals.
- the compounds ofthe invention are accordingly particularly effective in alleviating pain.
- said medicament is for use in alleviating pain and said patient is suffering from or susceptible to pain.
- the compounds ofthe invention are effective in alleviating both chronic and acute pain.
- Acute pain is generally understood to be a constellation of unpleasant sensory, perceptual and emotional experiences of certain associate autonomic (reflex) responses, and of psychological and behavioural reactions provoked by injury or disease.
- a discussion of acute pain can be found at Halpern (1984) Advances in Pain Research and Therapy, Nol.7, p.147.
- Tissue injury provokes a series of noxious stimuli which are transduced by nociceptors to impulses transmitted to the spinal cord and then to the upper part of the nervous system.
- Examples of acute pains which can be alleviated with the compounds ofthe invention include musculoskeletal pain, for example joint pain, lower back pain and neck pain, dental pain, post-operative pain, obstetric pain, for example labour pain, acute headache, neuralgia, myalgia, and visceral pain.
- Chronic pain is generally understood to be pain that persists beyond the usual course of an acute disease or beyond a reasonable time for an injury to heal. A discussion of chronic pain can be found in the Halpern reference given above. Chronic pain is sometimes a result of persistent dysfunction ofthe nociceptive pain system.
- Examples of chronic pains which can be alleviated with the compounds ofthe invention include trigeminal neuralgia, post-herpetic neuralgia (a form of chronic pain accompanied by skin changes in a dermatomal distribution following damage by acute Herpes Zoster disease), diabetic neuropathy, causalgia, "phantom limb” pain, pain associated with osteoarthritis, pain associated with rheumatoid arthritis, pain associated with cancer, pain associated with HIN, neuropathic pain, migraine and other conditions associated with chronic cephalic pain, primary and secondary hyperalgesia, inflammatory pain, nociceptive pain, tabes dorsalis, spinal cord injury pain, central pain, post-herpetic pain, noncardiac chest pain, irritable bowel syndrome and pain associated with bowel disorders and dyspepsia.
- trigeminal neuralgia a form of chronic pain accompanied by skin changes in a dermatomal distribution following damage by acute Herpes Zoster disease
- diabetic neuropathy causalgi
- neurogenic pain Some ofthe chronic pains set out above, for example, trigeminal neuralgia, diabetic neuropathic pain, causalgia, phantom limb pain and central post-stroke pain, have also been classified as neurogenic pain.
- One non-limiting definition of neuro genie pain is pain caused by dysfunction ofthe peripheral or central nervous system in the absence of nociceptor stimulation by trauma or disease.
- the compounds ofthe invention can, of course, be used to alleviate or reduce the incidence of neurogenic pain
- bowel disorders which can be treated or prevented with the compounds ofthe invention include inflammatory bowel syndrome and inflammatory bowel disease, for example Crohn's disease and ulcerative colitis.
- bladder dysfunctions which can be treated or prevented with the compounds ofthe invention include bladder hyper reflexia and bladder inflammation, for example interstitial cystitis, overactive (or unstable) bladder (OAB), more specifically urinary incontinence, urgency, frequency, urge incontinence and nocturia.
- the compounds ofthe invention can also be used to alleviate pain associated with bladder hyper reflexia or bladder inflammation.
- demyelinating diseases which can be treated or prevented with the compounds ofthe invention are those in which SNS channels are known to be expressed by the demyelinated neurones and which may or may not also have associated pain.
- a specific example of such a demyelinating disease is multiple sclerosis.
- the compounds of the invention can also be used to alleviate pain associated with demyelinating diseases such as multiple sclerosis.
- the compounds ofthe invention have additional properties as they are capable of inhibiting voltage dependent sodium channels. They can therefore be used, for example, to protect cells against damage or disorders which results from overstimulatibn of sodium channels:
- the compounds ofthe invention are useful in the treatment and prevention of peripheral and central nervous system disorders. They can therefore additionally be used in the treatment or prevention of an affective disorder, an anxiety disorder, a behavioural disorder, a cardiovascular disorder, a central or peripheral nervous system degenerative disorder, a central nervous system injury, a cerebral ischaemia, a chemical injury or substance abuse disorder, a cognitive disorder, an eating disorder, an eye disease, Parkinson's disease or a seizure disorder.
- affective disorders which can be treated or prevented with the compounds ofthe invention include mood disorders, bipolar disorders (both Type 1 and Type II) such as seasonal affective disorder, depression, manic depression, atypical depression and monodepressive disease, schizophrenia, psychotic disorders, mania and paranoia.
- anxiety disorders which can be treated or prevented with the compounds ofthe invention include generalised anxiety disorder (GAD), panic disorder, panic disorder with agoraphobia, simple (specific) phobias (e. g. arachnophobia, performance anxiety such as public speaking), social phobias, post- traumatic stress disorder, anxiety associated with depression, and obsessive compulsive disorder (OCD).
- GAD generalised anxiety disorder
- panic disorder panic disorder with agoraphobia
- simple (specific) phobias e. g. arachnophobia, performance anxiety such as public speaking
- social phobias e. g. arachnophobia, post- traumatic stress disorder
- anxiety associated with depression e.g. arachnophobia
- OCD
- behavioural disorders which can be treated or prevented with the compounds ofthe invention include behavioural and psychological signs and symptoms of dementia, age-related behavioural disorders, pervasive development disorders such as autism, Asperger's Syndrome, Retts syndrome and disintegrative disorder, attention deficit disorder, aggressivity, impulse control disorders and personality disorder.
- cardiovascular disorders which can be treated or prevented with the compounds ofthe invention include cardiac arrthymia, atherosclerosis, cardiac arrest, thrombosis, complications arising from coronary artery bypass surgery, myocardial infarction, reperfusion injury, intermittant claudication, ischaemic retinopathy, angina, pre-eclampsia, hypertension, congestive cardiac failure, restenosis following angioplasty, sepsis and septic shock.
- Examples of central and peripheral nervous system degenerative disorders which can be treated or prevented with the compounds ofthe invention include corticobasal degeneration, disseminated sclerosis, Freidrich's ataxia, m ⁇ tomeufone diseases such as amyotrophic lateral sclerosis and progressive bulbar atrophy, multiple system atrophy, myelopathy, radiculopathy, peripheral neuropathies such as diabetic neuropathy, tabes dorsalis, drug-induced neuropathy and vitamin deficiency, systemic lupus erythamatosis, granulomatous disease, olivo-ponto-cerebellar atrophy, progressive pallidal atrophy, progressive supranuclear palsy and spasticity.
- Examples of central nervous system injuries which can be treated with the compounds ofthe invention include traumatic brain injury, neurosurgery (surgical trauma), neuroprotection for head injuries, raised intracranial pressure, cerebral oedema, hydrocephalus and spinal cord injury.
- Examples of cerebral ischaemias which can be treated or prevented with the compounds ofthe invention include transient ischaemic attack, stroke, for example thrombotic stroke, ischaemic stroke, embolic stroke, haemorfhagic stroke or lacunar stroke, subarachnoid haemorrhage, cerebral vasospasm, peri-natal asphyxia, drowning, cardiac arrest and subdural haematoma.
- Examples of chemical injuries and substance abuse disorders which can be treated or prevented with the compounds ofthe invention include drug dependence, for example opiate dependence, benzodiazepine addition, amphetamine addiction and cocaine addiction, alcohol dependence, methanol toxicity, carbon monoxide poisoning and butane inhalation.
- Examples of cognitive disorders which can be treated or prevented with the compounds ofthe invention include dementia, Alzheimer Disease, Frontotemporal dementia, multi-infarct dementia, AIDS, dementia, dementia associated with Huntingtons Disease, Lewy body Dementia, Senile dementia, age-related memory impairment, cognitive impairment associated with dementia, Korsakoff syndrome and dementia pugilans.
- Examples of eating disorders which can be treated or prevented with the compounds ofthe invention include anorexia nervosa, bulimia, Prader-Willi syndrome and obesity.
- Examples of eye diseases which can be treated or prevented with the compounds ofthe invention include drug-induced optic neuritis, cataract, diabetic neuropathy, ischaemic retinopathy, retinal haemorrhage, retinitis pigmentosa, acute glaucoma, in particular acute normal tension glaucoma, chronic glaucoma, in ' particular chronic normal tension glaucoma, macular degeneration, retinal artery occlusion and retinitis.
- Parkinson's diseases which can be treated or prevented with the compounds ofthe invention include drug-induced Parkinsonism, post-encephalitic Parkinsonism, Parkinsonism induced by poisoning (for example MPTP, manganese or carbon monoxide poisoning), Dopa-responsive dystonia-Parkinsonism, posttraumatic Parkinson's disease (punch-drunk syndrome), Parkinson's with on-off syndrome, Parkinson's with freezing (end of dose deterioration) and Parkinson's with prominent dyskinesias.
- poisoning for example MPTP, manganese or carbon monoxide poisoning
- Dopa-responsive dystonia-Parkinsonism for example MPTP, manganese or carbon monoxide poisoning
- posttraumatic Parkinson's disease punch-drunk syndrome
- Parkinson's with on-off syndrome Parkinson's with freezing (end of dose deterioration)
- Parkinson's with prominent dyskinesias include drug-induced Parkinsonism, post-encephalitic Parkinsonism, Parkinsonism induced by poisoning (for example
- Examples of seizure disorders which can be treated or prevented with the compounds ofthe invention include epilepsy and post-traumatic epilepsy, partial epilepsy (simple partial seizures, complex partial seizures, and partial seizures secondarily generalised seizures), generalised seizures, including generalised tonicclonic seizures (grand mal), absence seizures (petit mal), myoclonic seizures, atonic seizures, clonic seizures, and tonic seizures, Lennox Gastaut, West Syndome (infantile spasms), multiresistant seizures and seizure prophylaxis (antiepileptogenic).
- the compounds ofthe present invention are also useful in the treatment and prevention of tinnitus.
- a therapeutically effective amount of a compound of he invention is administered to a patient.
- a typical dose is from about 0.001 to 50 mg per kg of body weight, for example 0.01 to 10 mg, according to the activity ofthe specific, compound, the age, weight and conditions ofthe subject to be treated, the type and severity ofthe disease and the frequency and route of administration.
- daily dosage levels are from 5 mg to 2 g.
- Example 60 The HPLC analysis of Example 60 was conducted in the following manner: Solvent: MeCN/H 2 O/0.05% NH 3 , 5-95% gradient H 2 O-10min; Column: Xterra 50 x 4.60 i.d., C18 reverse phase; and Flow rate: 1.5mL/min.
- reaction mixture was heated at 95°C for 7h and cooled to roorh temperature, 'filtered " and the solvent removed in vacuo
- the residue was dissolved in CH 2 C1 2 (80mL), washed with H 2 O (25mL), dried (Na 2 SO 4 ) and the solvent remove in vacuo .
- Example 10 2-[4,4-Bis-(4-fluoro-phenyl)-butyl]-8-methoxy-l,2,3,4-tetrahydro- isoquinoline Prepared according to the method described in Example 8. HPLC retention time 8.39min. Mass Spectrum (ES+) m/z 408(M+H).
- Example 20 N-(9H-Fluorenyl-9-yl)-2-(8-methoxy-3,4-dihydro-lH-isoquinoline- 2-yl)-acetamide Prepared according to the method described in Example 14. HPLC retention time 4.20min. Mass Spectrum (ES+) m z 385(M+H).
- Example 33 l-(3,4-Dihydro-lH-isoquinoUn-2-yl)-2-[[2-(3,4-dihydro-lH- isoquinolin-2-yl)-2-oxo-ethyl]-(3,3-diphenyl-propyl)-amino]-ethanone
- Example 34 l-(3,4-Dihydro-lH-isoquinoIin-2-y ⁇ )-2-(3,3-diphe- ⁇ yl-propyIamino)- ethanone
- Example 36 2- ⁇ (2,2-Diphenyl-ethyl)-[2-8-methoxy-3,4-dihydro-lH-isoquinolin- 2-yl)-2-oxo-ethyl]-amino ⁇ -lH-isoquinolin-2yl)-ethanone
- Example 37 2- ⁇ Benzhydryl-[2-(8-methoxy-3,4-dihydro-lH-isoquinolin-2-yl)-2- oxo-ethyl]-amino ⁇ -l-(8-methoxy-3,4-dihydro-lH-isoquinoli- ⁇ -2-yl)-etl ⁇ a ⁇ one
- Example 39 2-(2,2-Diphenyl-ethylamino)-l-(8-methoxy-3,4-dihydro-lH- isoquinolin-2-yl)-ethanone Prepared according to the method described in Example 31. HPLC retention time 6.65min. Mass Spectrum (ES+) m/z 401 (M+H).
- reaction mixture was stirred for a further 0.5h and quenched by pouring into a rapidly stirred biphasi solution of 15% potassium dihydrogen phosphate (150 mL) and methyl tert-butyl ether (160 mL). The organic layer was separated and washed with H O (2 xlOO mL).
- Example 52 8-Methoxy-3,4-dihydro-lH-isoquinolin-2-carbothioic " acid (2,2- diphenyl-ethyl)-amide
- Example 56 Example 2: N-Benzhydryl-2 ⁇ (4-methoxy-l,3-dihydro-isoindol-2- yl)-acetamide
- Example 60 2-(3,4-Dihydro-lH-isoquinolm-2-yl)-N-(2,2-diphenyl-ethyl)- acetamide Prepared according to the method described in Example 56. HPLC retention time 6.71min. Mass spectrum (ES+) m/z 371 (M + H).
- Example 62 l-(4-benzhydryI-piperazin-l-yI)-2-(8-methoxy ⁇ 3 ? 4-dihydro-lH- isoquinolin-2-yl)-ethanone l-(4-Benzhydryl-piperazin-l-yl)-2-chloro-ethanone: '
- Example 63 l- ⁇ 4-[Bis-(4-fluoro-phenyl)-methyl]-piperazin-l-yl ⁇ -2-(8-methoxy- 3,4-dihydro-lH-isoquinolin-2-yl)-ethanone
- Example 64 l-(4-Benzhydryl-piperazin-l-yl)-2-(3,4-dihydro-lH-isoquinolin-2- yl)-ethanone
- Example 65 l- ⁇ 4-[Bis-(4-fluoro-phenyl)-methyl]-piperazin-l-yI ⁇ -2-(3,4-dihydro- lH-isoquinolin-2-yl)-ethanone
- Example 68 l- ⁇ 4-[Bis-(4-fluoro-phenyl)-methyl]-piperazm-l-yl ⁇ -2-(l,3-dihydro- isoindol-2-yl)-ethanone Prepared according to the method described in Example 56. HPLC retention time - -4:5-2min. IH NMR (400 MHz (CD 3 ) 2 SO)D H 2:20-2.25 (4H),3.40-3.55-(6H), 3.90" (4H), 4.40 (IH), 7.05-7.20 (8H), 7.35-7.45 (4H). Mass spectrum (ES+) m/z 448 (M + H). ' Example 69: 2-(8-methoxy-3 5 4-dihydro-lH-isoquinolin-2-yl)-N-(phenyl-pyridin- 2-yl-methyl)-acetamide
- Example 70 2-(8-Hydroxy-3,4-dihydro-lH-isoquinolin-2-yl)-l-(3-phenyl-2,3- dihydro-benzo[l,4]oxazin-4-yI)-ethanone
- Example 74 N,N-Dibenzyl-2-(8-methoxy-3,4-dihydro-lH-isoquinolin-2-yl)- acetamide Prepared according to the method described in Example 56. HPLC retention time 4.57min. Mass spectrum (ES+) m/z 401 (M + H).
- Example 79 2-[3-(2,2-Diphenyl-vinyloxy)-propyl]-8-methoxy-l,2,3,4- tetrahydro-isoqumoline l-(3-Bromopropyloxy)-2,2-diphenylethene:
- Example 82 N-(3,3-Diphenyl-propyl)2-(7-methoxy-l,3,4,5-tetrahydro- benzo[c]azepin-2-yl)-acetamide Prepared according to the method described in Example 56. HPLC retention time 4.47min. Mass spectrum (ES+) m/z 429 (M + H).
- Phosphorous pentoxide (Fisher, P/3000/53) (14.2g, 50mmol) was added in portions to methanesulphonic acid (Avocado, 13565) (25mL), and the mixture was heated to 130°C [2-(4-Methoxy-phenyl)-ethyl]-carbamic acid methyl ester (5.23g, 25mmol) was added in portions and the mixture was heated at 140°C for a further lhr. The reaction was allowed to cool to ca.80°C and it was carefully added to ice with rapid stirring.
- Lithium aluminium hydride 1.0M solution in THF (Aldrich, 21,277-6) (0.42mL, 0.42mmol) was added drop wise to N,N-Dibenzyl-2-(7-methoxy-3,4-dihydro-lH- isoquinolin-2-yl)-acetamide (140mg, 0.35mmol). After addition the reaction was refluxed for 3hrs. The reaction was cooled to 0°C and quenched by the careful addition of deionised H 2 O (lmL), 10% NaOH solution (lmL) and deionised H 2 O (3mL).
- Example 102 2-(l ,3-Dihydro-isoindol-2-yl)-N-(3,3-diphenyl-propyl)acetamide
- Example 104 2-(8-AHyIoxy-3,4-dihydro-lH-isoqumolra-2-yl)-N-(3,3-diphenyl- propyl)acetamide
- Example 106 2-(4-Amino-l,3-dihydro-isoindol-2-yl)-N-(3,3-diphenyl- propyl)acetamide Prepared according to the method described in Example 14. HPLC retention time 4.02min. Mass Spectrum (ES+) m/z 386(M+H).
- N-[2-(Diphenylmethanesulphinyl)-ethyl]-2-(8-methoxy-3,4-dihydro-lH-isoquinolin- 2-yl)acetamide was prepared from N-(2-benzhydrylsulphanyl-ethyl)-2-(8-methoxy- 3,4-dihydro-lH-isoquinolin-2-yl)acetamide (leq) and mCPBA (leq) in CH 2 C1 2 to afford the title compound.
- Mass Spectrum (ES+) m/z 463(M+H).
- Example 111 N-[2- ⁇ iphenylmethanesulphonyl)-ethyl]-2-(8-methoxy ⁇ 3,4- dihydro-lH-isoqumolin-2-yl)acetamide N-[2-(Diphenyhnethanesulphonyl)-ethyl]-2-(8-methoxy-3,4-dihydro-lH-isoquinolin- 2-yl)acetamide was prepared from N-(2-benzhydrylsuIphanyl-ethyl)-2-(8-methoxy- 3,4-dihydro-lH-isoquinolin-2-yl)acetamide (leq) and mCPBA (2eq) in CH 2 C1 2 to afford the title compound. HPLC retention time 3.26min. Mass Spectrum (ES+) m/z 479(M+H).
- Example 117 2-[4,4-Bis-(4-fluorophenyl)-butyl]-l,2,3,4-tetrahydro-isoquinolin- 8-yIamine Prepared according to the method described in Example 14. HPLC retention time 4.60min. Mass Spectrum (ES+) m/z 393(M+H).
- Example 118 2-(8-Amino-3,4-dihydro-lH-isoquinolin-2-yl)-N-(2,2-dipkenyI- ethyl)acetamide- Prepared according to the method described in Example 14. HPLC retention time. 4.11 min. Mass Spectrum (ES+) m z 386(M+H).
- Example 120 N-[3,3-Bis-(4-methoxyphenyl)-propyl]-2-(l,3-dihydro-isoindol-2- yl)acetamide
- Example 122 N-[3,3-Bis-(4-methoxyphenyl)-propyl]-2-(8-methoxy-3,4-dihydro- lH-isoquinoIin-2-yI)acetamide
- N-(4,4-Diphenyl-butyl)-2-(8-methanesulphonylamino-3 ,4-dihydro- 1 H-isoquinolin-2- yl)acetamide was prepared from 2-(8-amino-3 ,4-dihydro- lH-isoquinolin-2-yl)-N- (4,4-diphenyl-butyl)acetamide (1 eq), methanesulphonylchloride (1 eq) and triethylamine (leq) in CH 2 C1 2 to afford the title compound. HPLC retention time 3.99min. Mass Spectrum (ES+) m/z 492(M+H).
- Example 127 N-[Bis-(4-fluorophenyl)methyl]-2-(8-methoxy-3,4-dihydro-lH- isoquinolin-2-yl) acetamide
- Example 128 N-[Bis-(4-fluorophenyl)methyl]-2-(6,7-dimethoxy-3,4-dihydro- lH-isoquinolin-2-yl)acetamide
- Example 132 3-(6,7-Dimethoxy-3,4-dihydro-lH-isoquinoUn-2-yl)-N-(3,3- diphenyl-propyI)propionamide Prepared according to the method described in Example 14. HPLC retention time 4.01min. Mass Spectrum (ES+) m z 459(M+H).
- Example 138 N-[3-(5-Chloro-2-methyI-indoI-l-yI)-propyl]-2-(8-hydroxy-3,4- dihydro-lH-isoquinolin-2-yI)acetamide
- Example 140 l-Benzhydryl-3-[2-(6,7-dimethoxy-3,4-dihydro-lH-isoquinolin-2- yl)-ethyl]-thiourea
- Example 142 l-Benzhydryl-3-[2-(6,7-dimethoxy-3,4-dihydro-lH-isoquinolin-2- yl)-ethyl]-urea
- Example 144 l-[2-(6,7-Dimethoxy-3,4-dihydro-lH-isoquinolin-2-yl)-ethyl]-3- (2,2-diphenyl-ethyl)-thiourea
- Example 147 l-(2-Chloro-phenothiazin-10-yl)-2-(8-hydroxy-3,4-dihydro-lH- isoquinolin-2-yl)-ethanone Prepared according to the method described in Example 56. HPLC retention time 4.33min. Mass Spectrum (ES+) m/z 4.23(M+H).
- Example 148 l-(2-Chloro-phenothiazin-10-yl)-2-(8-methoxy-3,4-dihydro-lH- isoquinolin-2-yl)-ethanone
- Example 151 2-(8-Hydroxy-3,4-dihydro-lH-isoquinolin-2-yl)-l-(2- trifluoromethyl-phenothiazin-10-yl)-ethanone
- Example 152 2-(8-Methoxy-3,4-dihydro-lH-isoquinolin-2-yl)-l-(2- trifluoromethyl-phenothiazin-10-yl)-ethanone
- Example 153 l-(2-Acetyl-phenothiazm-10-yl)-2-(8-hydroxy-3,4-dihydro-lH- isoquinolin-2-yl)-ethanone
- Example 154 1 -(2-Acetyl-phenothiazin-l 0-y l)-2-(8-methoxy-3,4-dihy dro-1 H- isoquinolin-2-yl)-ethanone
- Example 158 2-(6,7-Dimethoxy-3,4-dihydro-lH-isoquinolin-2-yl)-l- phenothiazin-10-yl-ethanone Prepared according to the method described in Example 56. HPLC retention time 4.19min. Mass Spectrum (ES+) m/z 433(M+H).
- Example 159 l-(2-Chloro-phenothiazin-10-yl)-2-(6,7-dimethoxy-3,4-dihydro- lH-isoquinolin-2-yl)-ethanone
- Example 162 2-(6,7-Dimethoxy-3,4-dihydro-lH-isoquinolin-2-yl)-l-(2- methylsulphanyl-phenothiazm-l 0-yl)-ethanone
- Example 164 2-(8-Hydroxy-3,4-dihydro-lH-isoquinolin-2-yl)-l-(2- methylsulphanyl-phenothiazin-l 0-yl)-ethanone
- Example 170 Phenoxazine-10-carboxylic acid [2-(8-methoxy-3,4-dihydro-lH- isoquinolin-2-yl)-ethyl]-amide
- Example 172 Phenoxazine-10-carboxylic acid [2-(6,7-dimethoxy-3,4-dihydro- lH-isoquinolin-2-yl)-ethyl]-amide
- Example 175 (8-Methoxy-3,4-dihydro-lH-isoquinolin-2-yI)-acetic acid N',N'- diphenyl-hydrazide
- Example 176 (6,7-Dimethoxy-3,4-dihydro-lH-isoquinolin-2-yl)-acetic acid N',N'-diphenyl-hydrazide
- Example 177 4-[2-(8-Hydroxy-3,4-dihydro-lH-isoquinolin-2-yl)-acetyl]-3,4- dihydro-2H-benzo[l,4]oxazine-2-carboxylic acid ethyl ester
- Example 178 4-[2-(8-Methoxy-3,4-dihydro-lH-isoquinolin-2-yl)-acetyl]-3,4- dihydro-2H-benzo[l,4]oxazine-2-carboxylic acid ethyl ester
- Example 180 2-(5,8-Dihydro-6H-[l,7]naphthyridin-7-yl)-l-phenoxazin-10-yl- ethanone Prepared according to the method described in Example 56 with the following modification: triethylamine was used as base. HPLC retention time 3.1min. Mass Spectrum (ES+) m/z 358(M+H).
- Example 181 l-[2-(8-Methoxy-3,4-dihydro-lH-isoquinolin-2-yl)-ethyl]-3-(4- phenoxyphenyl)-urea
- Example 186 2-(8-Hydroxy-3,4-dihydro-lH-isoquinolin-2-yl)-N-(9H-xanthen-9- yl)acetamide
- Example 191 2-(8-Methoxy-3,4-dihydro-lH-isoquinolin-2-yl)-N-(2- phenoxyphenyl)acetamide Prepared according to the method described in Example 56. HPLC retention time 4.77min. Mass Spectrum (ES+) m/z 389(M+H).
- Example 196 3-(8-Methoxy-3,4-dihydro-lH-isoquinolin-2-yl)-l-phenoxazin-l 0- yl-propan-1-one
- Example 200 2-(7-Hydroxy-3,4 ⁇ dihydro-lH-isoquinolin-2-yl)-l-phenoxazin-10- yl-ethanone
- Example 201 2-(6-Hydroxy-3,4 ⁇ dihydro-lH-isoquinolin-2-yl)-l-phenoxazin-10- yl-ethanone
- Example 202 2-(5-Hydroxy-3,4-dihydro-lH-isoquinolin-2-yl)-l-phenoxazin-10- yl-ethanone Prepared according to the method described in Example 56. HPLC retention time 3.89min. Mass Spectrum (ES+) m/z 373(M+H).
- Example 203 2-(4-Methoxy-l,3-dihydro-isoindol-2-yl)-l-phenoxazin-l 0-yl- ethanone
- Example 204 N-Methanesulphonyl-N- [2-(2-oxo-2-phenoxazin-l 0-yl-ethyI)- l,2,3,4-tetrahydro-isoquinoIin-8-yl]-methanesulphonamide
- Example 205 N-[2-(2-Oxo-2-phenoxazin-10-yl-ethyl)-l,2,3,4-tetrahydro- isoquinoIin-8-yl]-methanesuIphonamide
- Example 206 2-(8-Methoxy-3,4-dihydro-lH-isoquinoIin-2-yl)-l-(l-methyl-lH-4- oxa-l,2,9-triaza-cyclopenta[b]naphthalen-9-yl)-ethanone
- Example 207 2-(8- ethoxy-3,4-dihydro-lH-isoquinolm-2-yl)-l-phenoxazin-10- yl-propan-1-one
- Example 208 Phenoxazine-10-carboxylic acid [2-(5,8-dihydro-6H- [l,7]naphthyridin-7-yl)-ethyl]-amide
- Example 212 2-(8-Methoxy-3,4-dihydro-lH-isoquinoIin-2-yl)-l-(3-methyl-2,3- dihydro-benzo[l,4]oxazin-4-yl)-ethanone
- Example 213 l-(3-tert-Butyl-2,3-dihydro-benzo[l,4]oxazin-4-yl)-2-(8-methoxy- 3,4-dihydro-lH-isoquinolin-2-yl)-ethanone
- Example 214 l-(HH-Dibenzo[b,f][l,4]oxazepin-10-yl)-2-(8-methoxy-3,4- dihydro-lH-isoquinolin-2-yI)-ethanone
- Example 215 l-(3-Ethyl-2,3-dihydro-benzo[l,4]oxazin-4-yl)-2-(8-methoxy-3,4- dihydro-lH-isoquinolin-2-yl)-ethanone
- Example 218 l-(3-tert-Butyl-2,3-dihydro-benzo[l,4]oxazin-4-yl)-2-(8-hydroxy- 3,4-dihydro-lH-isoquinolin-2-yl)-ethanone Prepared according to the method described in Example 56. HPLC retention time 4.1 lmin. Mass Spectrum (ES+) m/z 381 (M+H).
- Example 220 l-[3-(2,5-Dimethoxyphenyl)-2,3-dihydro-benzo[l,4]oxazin-4-yl]-2- (8-methoxy-3,4-dihydro-lH-isoquinolin-2-yl)-ethanone
- Example 222 l-[3-(4-Fluorophenyl)-2,3-dihydro-benzo[l,4]oxazin-4-yl]-2-(8- methoxy-3,4-dihydro-lH-isoqumolin-2-yl)-ethanone
- Example 223 l-[3-(3,4-Dimethoxyphenyl)-2,3-dihydro-benzo[l,4]oxazin-4-yI]-2- (8-methoxy-3,4-dihydro-lH-isoquinolin-2-yl)-ethanone
- SH-SY-5Y hNa v 1.8 are grown in adherent monolayer culture using 50:50 Ham's F-12 / EMEM tissue culture medium supplemented with 15%> (v/v) foetal bovine serum; 2mM L-glutamine, 1%> NEAA and ⁇ OO ⁇ g.ml "1 Geneticin sulphate.
- Cells are removed from the tissue culture flask using trypsin/EDTA and re-plated into black walled, clear bottom 96-well assay plates at 50,000cells.weir " 24 hours prior to assay. On the day of assay the cell assay plates are washed to remove cell culture
- "" medium using a sodium free assay buffer (145mM tetiamethylahnnbrnurh chloride; 2mM calcium chloride; 0.8mM magnesium chloride hexahydrate; lOmM HEPES; lOmM glucose; 5mM potassium chloride, pH 7.4).
- Fluorescent membrane potential dye solution FLIPRTM membrane potential dye, Molecular Devices Corporation, containing lO ⁇ M of a pyrethroid to prevent channel inactivation and 250nM tetrodotoxin (TTX) to reduce interference from TTX-sensitive sodium channels present in the cell line.
- Test compound initially dissolved in dimethyl sulfoxide but further diluted in sodium free buffer, is added to achieve the final test concentration range of lOO ⁇ M - 0.05 ⁇ M.
- Cell plates are incubated for 30 minutes at room temperature to allow equilibration of dye and test compound. Plates are then transferred to a fluorescence plate reader for fluorescence measurement using an excitation wavelength of 530nm whilst measuring fluorescence emission at 565nm.
- Baseline fluorescence levels are first determined before the addition of a sodium containing buffer (220mM sodium chloride; 2mM calcium chloride; 0.8mM magnesium chloride hexahydrate; lOmM HEPES; lOmM glucose; 5mM potassium chloride.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des composés représentés par la formule générale (I) et certains de leurs sels pharmaceutiquement admis. Ces produits, qui s'avèrent des antagonistes des canaux sodium des neurones sensoriels, conviennent donc comme analgésiques et neuroprotecteurs. Dans cette formule, X est -N- ou -CH-, et 'n' vaut de 0 à 3.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0315872.2A GB0315872D0 (en) | 2003-07-07 | 2003-07-07 | Chemical compounds |
US48844203P | 2003-07-21 | 2003-07-21 | |
PCT/GB2004/002945 WO2005005392A1 (fr) | 2003-07-07 | 2004-07-07 | Composes azacycliques convenant comme inhibiteurs des canaux specifiques des neurones sensoriels |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1660454A1 true EP1660454A1 (fr) | 2006-05-31 |
Family
ID=34066606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04743288A Withdrawn EP1660454A1 (fr) | 2003-07-07 | 2004-07-07 | Composes azacycliques convenant comme inhibiteurs des canaux specifiques des neurones sensoriels |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1660454A1 (fr) |
WO (1) | WO2005005392A1 (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050165004A1 (en) * | 2004-01-22 | 2005-07-28 | Staffan Skogvall | Bronchorelaxing compounds |
GB0500300D0 (en) * | 2005-01-07 | 2005-02-16 | Ionix Pharmaceuticals Ltd | Chemical compositions |
GB0514018D0 (en) * | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
EP1998620B1 (fr) * | 2006-03-10 | 2011-01-12 | Neurogen Corporation | Piperazinyl-oxoalkyl-tetrahydroisoquinoleines et analogues apparentes |
EP1891958A1 (fr) | 2006-08-03 | 2008-02-27 | Universite Pierre Et Marie Curie (Paris Vi) | Inhibiteurs des kinases Rho/Rock/PI3/Akt pour le traitement des maladies associé aux parasites protozoaires |
MX2009012610A (es) | 2007-05-22 | 2009-12-11 | Astellas Pharma Inc | Compuesto de tetrahidroisoquinolina 1-sustituido. |
SE531698C2 (sv) | 2007-07-12 | 2009-07-07 | Respiratorius Ab | Nya bronkdilaterande a,b-omättade amider |
BR112013012078A2 (pt) | 2010-11-15 | 2019-09-24 | Abbvie Inc | inibidores de nampt e rock |
CN102060793B (zh) * | 2010-12-24 | 2013-03-20 | 西南大学 | 具生物活性的双芳基叔胺唑类化合物及制备方法和医药用途 |
CA2839703A1 (fr) | 2011-06-24 | 2012-12-27 | Amgen Inc. | Antagonistes de trpm8 et leur utilisation dans le cadre therapeutique |
MY157429A (en) | 2011-06-24 | 2016-06-15 | Amgen Inc | Trpm8 antagonists and their use in treatments |
US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
MX371017B (es) | 2014-02-03 | 2020-01-13 | Vitae Pharmaceuticals Llc | Inhibidores de dihidropirrolopiridina de receptor huerfano relacionado-gamma. |
KR20170066628A (ko) | 2014-10-14 | 2017-06-14 | 비타이 파마슈티컬즈, 인코포레이티드 | Ror-감마의 디히드로피롤로피리딘 억제제 |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
DK3331876T3 (da) | 2015-08-05 | 2021-01-11 | Vitae Pharmaceuticals Llc | Modulators of ror-gamma |
MX2018006223A (es) | 2015-11-20 | 2018-12-19 | Vitae Pharmaceuticals Inc | Moduladores de ror-gamma. |
TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ROR-γ調節劑 |
WO2017201683A1 (fr) | 2016-05-25 | 2017-11-30 | Merck Sharp & Dohme Corp. | Composés de tétrahydroisoquinoline substitués utiles à titre d'agonistes de gpr120 |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
WO2019018975A1 (fr) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | Inhibiteurs de ror gamma |
MA49685A (fr) | 2017-07-24 | 2021-04-14 | Vitae Pharmaceuticals Llc | INHIBITEURS DE ROR gamma |
WO2023172415A1 (fr) * | 2022-03-07 | 2023-09-14 | Firmenich Incorporated | Compositions d'édulcorants |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5767129A (en) * | 1995-08-24 | 1998-06-16 | Warner-Lambert Company | Substituted quinolines and isoquinolines as calcium channel blockers, their preparation and the use thereof |
WO2002051232A2 (fr) * | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Nouvelles benzazepines et derives heterocycliques associes |
US7244744B2 (en) * | 2001-11-01 | 2007-07-17 | Icagen, Inc. | Piperidines |
WO2003055848A2 (fr) * | 2001-12-26 | 2003-07-10 | Bayer Healthcare Ag | Derives d'uree |
-
2004
- 2004-07-07 EP EP04743288A patent/EP1660454A1/fr not_active Withdrawn
- 2004-07-07 WO PCT/GB2004/002945 patent/WO2005005392A1/fr active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of WO2005005392A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2005005392A1 (fr) | 2005-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005005392A1 (fr) | Composes azacycliques convenant comme inhibiteurs des canaux specifiques des neurones sensoriels | |
AU2016336437B2 (en) | Compounds, compositions, and methods for modulating CFTR | |
JP5730956B2 (ja) | 11−ベータヒドロキシルステロイドデヒドロゲナーゼタイプ1の阻害剤としてのスピロ環 | |
US7741315B2 (en) | HIV integrase inhibitors | |
EP0858996B1 (fr) | Agents de protection des cellules nerveuses | |
US20090082367A1 (en) | Triazole derivative or a salt thereof | |
CA3124317A1 (fr) | Derives d'heteroaryldihydropyrimidine et procedes de traitement d'infections par le virus de l'hepatite b | |
CN109661396A (zh) | 作为rock抑制剂的螺稠合环状脲 | |
KR20040035601A (ko) | Hiv 프로테아제 억제제, 이를 함유하는 조성물, 그의약학적 용도 및 그의 합성을 위한 물질 | |
US20100324017A1 (en) | Acylguanidine derivative | |
WO1996034863A1 (fr) | Nouvelle chimie heterocyclique | |
EP2352730A2 (fr) | Amides biologiquement actifs | |
US9598434B2 (en) | Benzazepine compound | |
ES2250345T3 (es) | Derivados sustituidos de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico. | |
US7148353B2 (en) | Imidazo[1,2-a] pyridine anxiolytics | |
CN105636961A (zh) | 哌嗪衍生物及其作为药物的用途 | |
EP1833797A1 (fr) | Composes azacycliques servant d'inhibiteurs de canaux specifiques aux neurones sensoriels (sns) | |
US20100105651A1 (en) | Antagonists of sns sodium channels | |
US20070043024A1 (en) | Azacyclic compounds as inhibitors of sensory neurone specific channels | |
JPWO2006115134A1 (ja) | 新規なベンゾフラン誘導体、それを含有する医薬組成物およびそれらの用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060130 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090202 |